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Design and Synthesis and Application of Chiral Diamine-
based Building Blocks via Diaza-Cope Rearrangement 
 
Much interest has been concentrated in the vininal diamine chemistry since 
many metal-based catalyst and organocatalysts as well as biologically active 
molecules containing the diamine structure have been synthesized. Diaza-
Cope rearrangement (DCR) is a versatile tool for providing a variety of 
symmetrically-substituted as well as non-symmetrically-substituted chiral 
vicinal diamines. As the DCR route was introduced, it has rendered the 
structural tuning and thus electronic diversification of diamino functionality at 
ease so that many chemists could discover and develop new catalysts and 
applications owing to the simplicity and effectiveness of the rearrangement. 
However, use of the DCR for the construction of chiral building blocks for 
physiologically active molecules or peptidomimetic structures has not been as 
actively pursued as for catalysts.  
The DCR allows for stereospecific synthesis of chiral vicinal diamines 
through the rearrangement of diimines prepared from 1,2-bis(2-
hydroxyphenyl)-1,2-diaminoethane (hpen) and aldehydes. With a broad 
perspective, the chiral nonsymmetrical 1,2-disubstituted vicinal diamines 
could serve as suitable intermediates for the preparation of many 
physiologically active compounds. Using the hpen as a starting material, a 
number of useful chiral molecules containing diamine functionality can be 
synthesized. 
Piperazine-2-carboxylic acid has been utilized as an amino acid surrogate in 
many biologically active compounds. In Chapter 1, the development of an 
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efficient route for enantiopure trans-3-arylpiperazine-2-carboxylic acid 
derivatives is described though the DCR process. A complete transfer of 
stereochemical integrity was observed for the transformation. Piperazine ring 
formation from the chiral 1,2-ethylenediamine derivatives using 
diphenylvinylsulfonium triflate, followed by oxidation using Ru(III)Cl3·H2O 
in the presence of NaIO4 provided the desired enantiopure trans-3-
arylpiperazine-2-carboxylic acid derivatives. 
The rearrangement also allows us to prepare γ,δ-diamino acids, which may 
be useful for the synthesis of Tamiflu-type antiviral agents as well as various 
biologically active compounds. In Chapter II, we report the one-pot reaction 
for the synthesis of γ,δ-diimino esters with two adjacent chiral centers in 
enantiomerically pure form through DCR of diimines formed from (R,R)-hpen 
and aldehydes. DFT computation provides interesting understanding into the 
stereospecific rearrangement reaction. The crystal structure of the product 
diimine formed from the reaction of (R,R)-hpen and 2,6-dichlorobenzaldehyde 
shows that the reaction gives the product in S,S configuration.  
Preparation of vicinal quaternary carbon centers containing vicinal diamines 
is synthetically challenging task. In Chapter III, we show that the synthesis of 
a twinned alanine derivative is efficiently accomplished through the DCR 
method. Reaction between (R,R)-hpen and methyl pyruvate gives the diaza-
Cope rearrangement product with good yield and excellent stereospecificity. 
The product containing two chiral quaternary carbon centers on vicinal 
position is characterized by high performance liquid chromatography (HPLC) 
and X-ray crystallography. DFT computation helps the understanding of why 
the diaza-Cope rearrangement takes place readily with methyl pyruvate but 
not with other ketones like acetone and substituted acetophenones. 
 The structural prevalence of chiral vicinal diamines as versatile chiral 
building blocks has led to an intense demand of useful tools to simply and 
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inexpensively determine the enantiomeric excess (ee) of the diamine 
molecules. In Chapter IV, we find that use of sugar molecules such as ribose 
and arabinose as chiral derivatizing agents is quite efficient in providing good 
analytical tool to determine the enantiopurities of C2-symmetric vicinal 
diamines. In this protocol, sugars or diamines do not need to be protected or 
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Vicinal diamine is a useful building block for biologically active compounds 
and commercially available drugs and drug candidate molecules. The vicinal 
diamine functionality is often embedded in bioactive molecules through their 
own structure as well as other moieties such as imidazoldine, piperazine, 
piperidine, β-lactam and γ,δ-diamino acid (Figure 1).1 For example, 1,2-
diaminocylohexane (dach) moiety was used to synthesize Oxaliplatin (1), an 
anticancer drug,2 and U-50,488 (2), a highly selective κ-opioid agonist.3  
 
 
Figure 1. Diamine-based Bioactive Molecules. 
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Among others, examples of imidazolidine-type diamines such as Nutlin-3 (3), 
an anticancer drug4 and 4,5-diaryl imidazoline derivatives (4), a P2X7 receptor 
antagonist,5 have been reported, both of which contain meso-vicinal diamine 
structures. Molecules embedding heterocyclic structures including piperazine 
and piperidine exhibit various biological activities such as inhibition of HIV 
protease (Indinavir, 5),6 inhibition of MMP-13, TNF-α converting enzyme 
(6),7 CP-99,994 (7) and CP-96,345 (8) showing antidepressant, anxiolytic 
antiemetic properties as a NK1 receptor antagonists,








as penicillins (9)9 and loracarbef (10)10 are used in the treatment of bacterial 
infection. Oseltamivir (11) and Zanamivir (12) exhibit potent antiviral activity 
and have γ,δ-diamino acid functionality in their skeleton. They serve as potent 
lead compounds for developing neuraminidase inhibitors.11 
Vicinal diamine-based molecules are also crucial components in the design 
and synthesis of various chiral catalysts, and these molecules have been used 
in stereoselective organic synthesis, for example as ligands for transition 
metal-based catalyst and organocatalysts (Figure 2). Examples of reactions 
utilizing chiral diamines as the ligands of transition metal-based catalysts 
include various reactions such as transfer hydrogenation,12 hydrogenation,13 
asymmetric Heck reaction,14 olefin metathesis,15 epoxidation16 and 
asymmetric ring opening reaction.17 Also, organocatalysts with vicinal 
diamino functionalities have been used for asymmetric Strecker reaction,18 





The production of 1,2-diphenyl-1,2-diaminoethane (dpen, Eq. 1) 21 and 1,2-
diaminocyclohexane (dach, Eq. 2)22 have been of considerable interest for the 
construction of a large number of metal-based catalysts and organocatalysts as 
well as biologically active therapeutic agents over several decades as 
previously shown. However, individual synthesis of a wide variety of diamine 
structures was required to develop and discover better catalysts and bioactive 
molecules. For this reason, previous syntheses of C2-symmetric chiral vicinal 
diamines having aryl or alkyl substituents are highlighted herein. In 1995, 
Corey et al.23 reported a synthetic route for chiral 1,2-diaryl-1,2-
diaminoethane (Eq. 3). They used aryl-substituted benzil analogs as a starting 
material to prepare corresponding imidazole intermediate, followed by Birch 
reduction and hydrolysis. The obtained products were neutralized, then 
resolved through the use of tartaric acid to give (R,R)- and (S,S)-1,2-diaryl-
1,2-diaminoethane. Pedersen and coworkers24 showed that chiral vicinal 
diamines could be prepared through the coupling of nitriles or N-
(trimethylsilyl)imines mediated by NbCl4(THF)2 (Eq. 4). The synthetic 
method is originated from the resonance structure of a simple d1 N-metal 





ed by hydrolysis to yield racemic aryl or alkyl substituted vicinal diaimines. 
Both methods are among the most used pathways for the synthesis of racemic 
vicinal diamines, however, the racemic mixture needs to be separated into two 
enantiomers through chiral resolution, which often result in low overall yields. 
 
 
There have been diverse approaches to synthesize chiral vicinal diamines 
directly. Xu and coworkers25 have discovered highly diastereoselective and 
enantioselective synthesis of C2-symmetric vicinal diamines through efficient 
reductive homocoupling of chiral N-tert-butanesulfinylimines in the presence 
of SmI2 and HMPA (Eq. 5). This method gives chiral dpen derivatives in 
excellent enantioselectivity in varying yields. Salvadori and coworkers26 have 
developed a four step route using trans-stilbene as starting material, which is 
easily converted to enantiopure diol by Sharpless asymmetric dihydroxylation 
(AD) (Eq. 6). Tosylation of the chiral diol and subsequent double 
displacement by sodium azide provides azide intermediate, which is then 
reduced with LAH to provide 1,2-diphenyl-1,2-diaminoethane in >99 % ee. 
16 
 
Alexakis’ group27 introduced a diastereoselective synthesis of alkyl 
substituted vicinal diamines through the addition of t-butylmagnesium 
chloride to a chiral bis-imine derivative prepared from chiral 
methylbenzylamine and glyoxal (Eq. 7). 
Chiral dpen was also used as a starting material for chiral diamine. Chiral 
1,2-dicyclohexylethylenediamines were synthesized by hydrogenation of dpen 
hydrochloride in presence of platinum(IV) oxide (Eq. 8).28 
 
 
As described previously, various approaches have been investigated to devise 
efficient synthetic methods for chiral vicinal diamines. However, for 
developing better catalysts and improving biological activities of drugs and 
drug candidates, it has been a challenge to develop general and yet efficient 
synthetic way to a wide variety of enantiomerically pure vicinal diamines. 
Recently, Chin and coworkers29 have developed a useful method for 
synthesizing chiral vicinal diamines through DCR. The rearrangement 
reaction was first reported in 1973 by Vögtle and Goldschmitt for the 
synthesis of a wide range of meso-1,2-diamines.30 Chin and coworkers 
reported that the completion of the rearrangement reaction is derived from 
resonance assisted hydrogen bonding (RAHB) that dramatically shift the 
reaction equilibrium to one side.31 The concept of resonance assisted 
hydrogen bonding has also played an important role in endogenous enzymatic 
reactions that catalyze a large number of biochemical reactions, including the 
biosynthesis of amino acids by the pyridoxal-5’-phosphate-dependent 
enzymes (PLP enzymes) (Scheme 1).32 As exemplified in Scheme 1, the 
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transamination converting an internal aldimine into an external one is 
thermodynamically favorable (-12 kcal/mol) and stabilized by RAHB. Based 
on the importance of the H-bond effect in biosystem, Gilli et al.33 investigated 
that RAHB is a model of synergistic interplay between H-bond strengthening 
and π-delocalization. This study explained the abnormally strong 
intramolecular hydrogen bond induced by resonance effect in various 
molecules using IR, X-ray and DFT calculation.  
 
Scheme 1. Catalytic Mechanism for the Transamination Reaction of PLP-
Dependent Coenzymes (P represents the phosphate group). 
 
These seminal works on the DCR by Vȍgtle et al. and on the RAHB by Gilli 
et al. have led to the development of RAHB-directed DCR. Since Chin’s 
group introduced the new synthetic method using the DCR starting from 
(R,R)/(S,S)-1,2-bis(2-hydroxyphenyl)-1,2-diaminoethane (hpen), which is 
called ‘mother diamine’, a variety of C2-symmetric aryl or alkyl substituted 
vicinal diamines with exceptionally high enantiopurities have been 




Scheme 2. Synthesis of Chiral C2-symmetric Vicinal Diamines via DCR. 
 
Figure 3. Possible Transition States for the Chirality Transfer Through DCR. 
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In case of the synthesis of aryl-substituted diamines,34 addition of 2 equiv of 
aryl aldehyde to (R,R)-hpen in the presence of solvent such ethanol or 
dimethylsulfoxide (DMSO) results in the formation of the corresponding 
initial diimines, followed by efficient [3,3]-sigmatropic rearrangement. The 
product diimines are then hydrolyzed to furnish the desired product diamines 
in acidic conditions. In case of the synthesis for alkyl substituted diamines,35 
refluxing the reaction mixture for 24 h in toluene instead of EtOH or DMSO 
was required. The product diimines are then hydrolyzed by acidic cleavage to 
provide the desired product diamines. All the diamines obtained thus far 
exhibit >99% enantiomeric purities. 
To gain some insights into the origin of the chirality transfer, three possible 
chair-like transition states are considered where substituents are located on 
different positions in each transition state (Figure 3).29a Among them, 
transition state A is considered to be the most stable because all four 
substituents are in the equatorial positions with the smallest 1,3-diaxial 
interaction in six membered conformation. Therefore, the product diimine of 
the reaction converged into one enantiomer resulting in the stereospecific 
transfer of the stereochemistry. 
 
Scheme 3. Stereospecific Synthesis of -Substituted syn-,β-Diamino Esters. 
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The Chin group also reported the stereospecific synthesis of -substituted 
syn-,β-diamino esters, which are used as versatile building blocks for natural 
amino acid analogues and enzyme inhibitors through DCR with complete 
transfer of chirality derived from (R,R)-hpen (Scheme 3).36 This meaningful 
study showed that the rearrangement is also utilized for synthesizing chiral 
vicinal diamines possessing a quaternary chiral carbon center.  
With the ease and effectiveness of the DCR with ready availability of hpen, 
wide ranging applications of the method have been published including tuning 
of the reactivity and stereoselectivity of transition metal based catalysts and 
organocatalysts (Figure 4).  
 
 
Figure 4. Various Applications of hpen in Transition Metal Catalysts and 
Organocatalysts. 
 
Carreira37 and Deng38 developed Ir(III) and Ru(II) complex catalysts with 
tuning of diamine backbones that were synthesized from chiral hpen. These 
catalysts were then optimized for the transfer hydrogenation reaction of 
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substituted nitroalkenes and acetophenones. Johnson39 also used structural 
variants of vicinal diamines to give the diversity in the catalyst, thus 
enhancing the selectivity and the reactivity of catalysts for dynamic kinetic 
resolution of -keto esters. Additionally, Fu40 developed the diamines based 
Ni(II) complex for asymmetric Suzuki coupling reaction and asymmetric 
Negishi -alkylation. The catalysts have been optimized by tuning chiral 
diamine backbones from hpen. Huang and Xia41 designed a new and efficient 
chiral bisisoindoline and its isomer with rigid backbones. These structures 
were prepared using the rearrangement reaction starting from hpen and were 
employed as a ligand in the Ni(II) catalyzed Michael addition reaction of 
malonates to conjugated nitroalkenes. For organocatalyst, Chin42 introduced 
the substrate-directed reaction for synthesizing Warfarin using C2-symmetric 
vicinal diamines that were tuned by changing substituents on the diamine-
based skeleton.  
Other applications have been developed over various areas in chemistry. 




Figure 5. Other Applications of DCR. 
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anion developed by Hong and Kim were easily synthesized by DCR.43 Also, 
Akine and Nabeshima44 developed helical molecular levers with a novel 
crown ether chiral dpen derivative moiety starting from hpen. Cooper and 





RAHB-directed DCR is a powerful method for the synthesis of a large 
number of chiral vicinal diamines as well as non-symmetrically substituted 
vicinal diamines since Vögtle introduced DCR for meso diamines. Also, it 
facilitates the structural tuning and electronic diversity of diamine 
functionality for the discovery and development of new transition metal based 
catalysts, organocatalysts and other applications. However, the diaza-Cope 
rearrangement has not found much use in the synthesis of chiral building 
blocks for biologically active compounds or peptidomimetic structures 
compared to the use for catalysts. This thesis is therefore focused on the 
development of novel synthetic methods for highly substituted chiral 
piperazines, chiral γ,δ-diamino ester and twinned alanine ester as key 
intermediates for the construction of therapeutically active agents. In addition, 
the use of ribose and arabinose as chiral derivatizing agents (CDAs) for the 
determination of the enantiopurities of various C2-symmetric vicinal diamines 











Synthesis of Chiral  
trans-3-Arylpiperazine-2-carboxylic 






Piperazine is a versatile building block often employed in the design of 
physiologically active compounds.1 Among various substituted piperazine 
structures, piperazine-2-carboxylic acid derivatives can be regarded as novel 
amino acid surrogates and therefore have been utilized in various 
peptidomimetic structures for therapeutically important molecules. Examples 
of chiral piperazine-2-carboxylic acid derivatives embedded in drug 








cholecystokinin-1 receptor (CCK1R) agonists,3 κ-receptor agonists,4 substance 
P (SP) receptor antagonists,5 N-methyl-D-aspartic acid (NMDA) antagonists,6 
and MMP-13 and TNF-α converting enzyme inhibitors (Figure I-1).7 
Although much research has been carried out for the synthesis of optically 
active piperazine-2-carboxylic acid derivatives, preparation of stereodefined 
3-, 5- or 6-substituted piperazine-2-carboxylic acid derivatives in an 
enantiomerically pure form is still a challenging synthetic problem. Previously, 
chiral piperazine-2-carboxylic acid derivatives have been prepared through 
cyclizations,8 multicomponent synthesis,9 amino acid-based synthesis,10 
enzymatic resolution,11 asymmetric hydrogenation of pyrazine derivatives,12 
α-lithiation of piperazine using s-BuLi/(-)-sparteine13 and Pd-catalyzed 
asymmetric allylic allylation.14 However, some of these methods suffer from 
shortcomings such as the problem of catalyst traces remaining in final 
product(s), low enantiopurity of final compounds and low yields resulting 
from complicated multistep route. In the course of our medicinal chemistry 
programs, we were in search of an efficient method for the preparation of 
trans-3-arylpiperazine-2-carboxylic acid derivatives and have found that there 
are scarce reports on them.8g To obtain 3-substituted piperazine-2-carboxylic 
acids, SN2-type cyclization and the reduction of 2,3-disubstituted 
ketopiperazines derived from chiral 1,2-diamines have been previously 
used.
7,8g
 For the latter method, synthesis of suitably substituted enantiopure 
chiral vicinal diamines is essential. We have recently developed a 
stereospecific synthesis of C2-symmetric chiral vicinal diamines through the 
diaza-Cope rearrangement (DCR) of chiral initial diimines prepared from the 
reaction of (R,R)/(S,S)-1,2-bis(2-hydroxyphenyl)-1,2-diaminoethane (hpen) 
and 2 equiv of aldehydes.15 The rearrangement reaction was nicely extended 
to a stereospecific “one pot” route to α-substituted syn-α,β-diamino esters.16 
We envisioned that the chiral nonsymmetrical 1,2-disubstituted vicinal 
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diamines synthesized by diaza-Cope rearrangement (DCR) could serve as 
suitable intermediates for the preparation of chiral nonsymmetrical 2,3-
substituted piperazines. Herein, we demonstrate on the development of an 
efficient route to enantiomerically pure trans-3-arylpiperazine-2-carboxylic 
acids starting from chiral hpen via DCR using various aryl aldehydes and 
trans-cinnamaldehyde. 
 
I-2. Result and Discussion 
 
Toward the construction of structurally diverse trans-3-arylpiperazine-2-
carboxylic acids, formation of the unsymmetrically substituted diimines was 
studied from the reaction of hpen with benzaldehyde and trans-
cinnamaldehyde. To find optimal reaction conditions, factors such as solvent, 
temperature and stoichiometry of aldehydes were investigated. From solvent 
screening experiments using dimethyl sulfoxide (DMSO), tetrahydrofuran 
(THF) and toluene, DMSO was quickly identified as the solvent of choice. As 
for the reaction stoichiometry, 1 equiv of aryl aldehyde and 1 equiv of trans-
cinnamaldehyde were found to be optimal for the reaction. The reactions 
proceeded smoothly at ambient tem74perature, and reactions at higher 
temperatures did not improve the yield. Since two different aldehydes are 
involved in the reaction to form heterodimeric diimine product, the hetero- 
versus homodimer selectivity is critical. It was found that the best heterodimer 
selectivity was obtained when an aminal 2 was first formed and then was 
subjected to the reaction with trans-cinnamaldehyde, as outlined in Scheme 
I-1. The formation of the aminal 2 was accomplished through slow addition 
of an aryl aldehyde to the solution of hpen. The structure of aminal 2 was 
confirmed from 1H NMR spectral analysis of a crude reaction mixture in 
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DMSO-d6. This aminal 2 was then subjected to the reaction with trans-
cinnamaldehyde without isolation. Addition of trans-cinnamaldehyde to aminal 
2 then allowed for the formation of diimine 3, which was smoothly 
converted to the desired product diimine 4 facilitated by the RAHB.17 The 
formation of diimine 4 as a major product was observed along with small 





Scheme I-1. Stereospecific Synthesis of Diimine via DCR. 
 
With the optimized reaction conditions in hand, various aryl aldehydes were 
investigated in the formation of compound 2 to insure structural diversity of 
the chiral piperazine derivatives. Excellent yields (mostly >90%) of aminal 
intermediates 2 were observed as determined by NMR analysis.18 In this step, 
slow addition of the aryl aldehyde was found to be critical to minimize the 
formation of homodimeric diimine product 5 or 6. Subsequently, the 
formation of heterodimeric diimine 4 as a major product was confirmed 12 h  
after addition of 1 equiv trans-cinnamaldehyde. 
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Entry Product Ar Yield (%)b   4/5/6 ratiob,c 
1 4a Ph 89 88/7/5 
2 4b 4-FC6H4 91 88/7/5 
3 4c 4-ClC6H4 91 91/4/5 
4 4d 2-BrC6H4 86 97/2/1 
5 4e 3-BrC6H4 91 91/6/3 
6 4f 4-BrC6H4 83 91/4/5 
7 4g 1-Naphthyl 90 89/7/4 
8 4h 2-Pyridyl 82 94/4/2 
9 4i 4-OMeC6H4 71 79/13/8 
10 4j 4-Acetamidophenyl 74 80/11/9 
 
a Reagents and conditions: (a) ArCHO, DMSO, rt, 1 h; (b) trans-cinnamaldehyde, 
rt, 12 h.  
b Determined by 1H NMR analysis of the crude mixture.  
c The relative Rf values of the homodimeric side products compared to the desired 
heterodimeric product vary depending upon their structures. 
 
 
As can be seen in Table I-1, the yields of heterodimeric diimine 4 were 
dependent upon the substituents on aryl aldehydes. Diimines formed from an 
aryl aldehyde containing electron-withdrawing or halide substituents were 
obtained in good to excellent yields (entries 2-6) with good hetero/homo 
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product ratios, which were determined through 1H NMR analysis.18 Diimines 
formed from 1-naphthyl and heteroaromatic aldehydes were also obtained in 
satisfactory yields (entries 7 and 8). On the other hand, reactions of p-
methoxybenzaldehyde and 4-acetamidobenzaldehyde gave moderate yields of 
product diimines and slightly higher ratios of unwanted homodimeric 
diimines (entries 9 and 10, respectively). 
Formation of the homodimeric product 6 of trans-cinnamaldehyde is 
believed to come from the very nature of the reaction, which involves the 
equilibrium from hpen and two aldehydes to the very end product, thus 
allowing for disproportionation after addition of trans-cinnamaldehyde. 
Attempts to purify the heterodimeric diimine products from the homodimeric 
diimines on a silica gel column were accompanied by some decomposition of 
the diimine species. Therefore, we decided to purify the heterodimeric product 
at a later stage.  
 
Table I-2. Synthesis of N-Ns-Protected Vicinal Diaminesa 
 
 
Entry Product Ar Yield (%)b Ee (%)e 
1 8a Ph 79 >99 
2 8b 4-FC6H4 86 >99 
3 8c 4-ClC6H4 84 >99 
4 8d 2-BrC6H4 84 >99 
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5 8e 3-BrC6H4 83 >99 
6 8f 4-BrC6H4 91 >99 
7 8g 1-Naphthyl 76 >99 
8 8h 2-Pyridyl 74
c,d >99 
9 8i 4-OMeC6H4 76 >99 
10 8j 4-Acetamidophenyl 59 >99
f 
 
a Reagents and conditions: (a) 2.5 equiv of conc. HCl in THF (0.1M); (b) 4 equiv of 
4-NsCl, 6 equiv ofTEAinTHF(0.1 M).  
b Yields of isolated products after column chromatography.  
c Excess (3.5 equiv) conc. HCl was used.  
d In this reaction, 8 equiv of TEA was used in dichloromethane.  
e Values of ee were determined through chiral HPLC analysis using Chiralpak IA 
column.  
f Value of ee was determined at the chiral diimine 4j stage. 
 
 
Hydrolysis of diimine 4 and subsequent protection of the resulting diamine 7 
was carried out, and the data are shown in Table I-2. Upon hydrolysis of 
diimines 4a-j using concentrated HCl, diamine HCl salts 7a-j were obtained 
as precipitates. HCl salts 7a-j underwent smooth reaction with 4-
nitrobenzenesulfonyl chloride (NsCl) and triethylamine (TEA) in THF to give 
N,N’-bisNs-protected vicinal diamines 8a-j in good overall yields (59-91% for 
the two steps). Enantiomeric purities of the product diamines were determined 
at this stage through chiral HPLC analysis, and all of them were uniformly 
high (>99% ee). 
 




Entry Prt Base Time Yield (%) 
1 -H TEA 12 h 11
b 
2 -Bz DBU 24 h trace 
3 -Boc KOH 12 h 47
c 
4 -CF3CO DBU 12 h 66 
5 -Ts DBU 4 h 82 
6 -Ns DBU 4 h 84 
 
a Reagents and conditions. 1.2 equiv diphenylvinylsulfonium triflate 11 and 2.2 
equiv base were used in DCM (0.02 M).  
b The product was purified after N-Boc protection.  
c In this reaction, 6 equiv KOH and 6 equiv 18-crown-6 was used. 
 
 
 In 2008, Aggarwal et al. reported an annulation reaction for the synthesis of 
piperazines from ethylenediamine derivatives using diphenylvinylsulfonium 
triflate (11).19 We took compound 7a to study optimal reaction conditions for 
the construction of piperazine structures using Aggarwal’s protocol. First, 
reactions using Aggarwal’s diphenylvinylsulfonium triflate (11) were 
attempted on the free diamine of 7a; however, the reaction was very sluggish, 
yielding only 11% of the desired piperazine product, which was confirmed 
after N-Boc protection. Diamines having various N,N’-protecting groups such 
as Boc, CBz, CF3CO, Ts and Ns groups, which are associated with different 
pKa values,
20
 were screened for the construction of piperazine ring (Table I-3). 
The reaction from N,N’-diBz-protected diamines gave almost no desired 
product at all. However, 47% yield of the desired piperazine ring was 
obtained in the reaction of the N,N’-bisBoc-protected diamine using 
potassium hydroxide as a base and 18-crown-6 as an additive to improve the 
solubility of KOH in the reaction. When more acidic N,N’-diNs or diTs 
groups, which allow lower pKa values on the nitrogen atoms compared to 
other protecting groups, were employed as protecting groups, the reactions 
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proceeded in good yields (82 and 84%, respectively). Even though both N,N’-
diTs- and N,N’-diNs-protected diamines provided good yields of the desired 
product, N,N’-diNs protection, which can be deprotected via treatment with 
PhSH and K2CO3 in dimethylforamide (DMF),
21 was preferred since harsh 
reaction conditions would be required for the removal of the N,N’-diTs group. 
The N,N’-diNs protection provided another advantage where, at this stage, the 
heterodimeric amines were easily separable from the homodimeric diamine 
derivatives through silica gel column chromatography.  
With the optimal protecting group selected, another substrate having a 4-
bromophenyl substituent (8f) was tested for the ring forming reaction with 
diphenylvinylsulfonium triflate 11, and the reaction proceeded in 89% yield, 
showing the generality of this cyclization. Eventually, the double bond 
moieties of 9a and 9f were efficiently oxidized into carboxylic acids via 
oxidation using ruthenium (III) chloride monohydrate with sodium periodate22 
in 74 and 72% yields, respectively (Scheme I-2). 
 
 






A simple, yet highly efficient synthetic route for enantiopure trans-3-
arylpiperazine-2-carboxylic acids as exemplified in 10a and 10f starting from 
hpen as a chiral starting material with various aryl aldehydes and trans-
cinnamaldehyde has been developed. The chiral starting material, that is hpen, 
transfers its chirality to the product diimines, eventually leading to the 
formation of chiral piperazines in highly enantiopure form. Use of the chiral 
3-arylpiperazine-2-carboxylic acids as an artificial amino acid analogue in the 
construction of physiologically active compounds is in progress and will be 




General Information  
 
The 1H and 13C NMR-spectra were measured with a Bruker DPX-300 (300 
MHz) and a Varian/Oxford As-500 (500 MHz) spectrophotometer. 19F NMR-
spectra were measured with a Bruker, Avance-300 (300 MHz). Chemical 
shifts were measured as part per million (δ values) from tetramethylsilane as 
an internal standard at probe temperature in CDCl3 or corresponding 
deuterated solvents for neutral compounds. High resolution mass spectra 
(HRMS) were recorded on a ThermoFinnigan LCQ™ Classic, Quadrupole 
Ion-Trap Mass Spectrometer. HPLC analysis was performed on a Hewlett-
Packard 1100 Series HPLC, UV detection monitored at 254.4 nm, using a 
Chiralpak®  IA column (25 cm) or a Chiralcel OD-H column (25 cm). Optical 
rotation data were obtained on a JASCO P-1030 automatic polarimeter.  
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Melting points were recorded using an Electrothermal Melting Point 
Equipment IA 8103. Reactions that needed anhydrous conditions were carried 
out in flame-dried glassware under positive pressure of dry N2 using standard 
Schrenk line techniques. Evaporation of solvents was performed at reduced 
pressure using a rotary evaporator. TLC was performed by silica gel 60 F254 
coated on aluminum sheet (E. Merck, Art.5554). Chromatogram was 
visualized by UV-lamp (Vilber Lournat, VL-4LC). Column chromatography 
was performed on silica gel (Merck 9385 Kiesel gel 60), and eluent was 
mentioned in each procedure. All materials were obtained from commercial 
supplier and used without further purification. 
 





To a stirred solution of 100 mg (0.41 mmol) of (R,R)-1,2-bis(2-
hydroxyphenyl)-1,2-diaminoethane (hpen) in 1.2 mL of dimethylsulfoxide 
(DMSO) was slowly added 0.41 mmol of arylaldehyde in 0.2 mL of DMSO 
for 3 minutes using a syringe pump. The resulting solution was stirred for 1 h 
at room temperature. The formation of imidazolidine 2 was confirmed by 
taking 1H NMR spectra of the reaction mixture in DMSO-d6. 51.5 μL (0.41 
mmol) of trans-cinnamaldehyde was added to the reaction mixture for 
minutes. 1H NMR spectroscopy was used to monitor the progress of the 
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reaction and to determine the ratio between (S,S)-4, (S,S)-5, (S,S)-6. After 
stirring at room temperature for 12 h, the reaction mixture was mixed with 
iced-cold distilled water and extracted with diethyl ether. The combined 
organic layers were washed with distilled water twice and dried over 
anhydrous MgSO4, filtered, and concentrated under reduced pressure. The 
obtained products were used for further reactions as obtained, without 
additional purification. (In the case of 4j, diimine 4j should be separated to 
determine enantiomeric excess of N-Nosyl diamine 8j because we could not 
determine enantiomeric excess of 8j. 
 
Compound (S,S)-4j 
To a stirred solution of 100 mg (0.41 mmol) of 
(R,R)-hpen in 1.2 mL of DMSO was slowly added 
0.41 mmol of 4-acetamidophenylbenzaldehyde in 
0.2 mL of DMSO for 3 minutes using a syringe 
pump. The resulting solution was stirred for 1 h at room temperature. 51.5 μL 
(0.41 mmol) of trans-cinnamaldehyde was added to the reaction mixture for 
minutes. After stirring at room temperature for 12 h, the reaction mixture was 
mixed with iced-cold distilled water and extracted with diethyl ether. The 
combined organic layers were washed with distilled water twice and dried 
over anhydrous MgSO4, filtered, and concentrated under reduced pressure. 
The residue was separated by column chromatography (Hexane/EtOAc) to 
afford 4j as a solid. Yellow solid (52% yield), mp 228 ℃, Rf = 0.35 
(Hexane:EtOAc = 1:1) 1H NMR (499 MHz, CDCl3): δ 13.32 (s, 1H), 13.25 (s, 
1H), 8.34 (s, 1H), 8.30 (s, 1H), 7.71 (s, 1H), 7.50 (d, J = 8.0 Hz, 2H), 7.33 (d, 
J = 7.9 Hz, 2H), 7.25 – 7.14 (m, 9H), 6.93 (t, J = 9.2 Hz, 2H), 6.80 (dd, J = 
12.0, 7.2 Hz, 2H), 6.45 (d, J = 16.0 Hz, 1H), 6.16 (dd, J = 16.0, 6.7 Hz, 1H), 
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4.59 (d, J = 6.7 Hz, 1H), 4.39 (t, J = 6.6 Hz, 1H), 2.10 (s, 3H); 13C NMR (126 
MHz, CDCl3): δ 168.8, 166.5, 166.3, 161.20, 161.17, 138.0, 136.6, 135.5, 
133.1, 132.9, 132.1, 128.8, 128.7, 128.1, 127.4, 126.7, 120.2, 119.09, 119.05, 
118.9, 118.8, 117.21, 117.15, 78.2, 76.9, 24.8; The enantiopurity was 
confirmed by HPLC analysis (Chiralpak®  IA column, 100% Ethyl alcohol + 
diethyl amine (DEA) 0.1%, 0.3 ml/min); rac-4j tR = 47.7 min tR = 71.0 min. 
(S,S)-4j tR = 47.4 min.; HRMS (ESI) calculated C32H30O3N3 [M+H]
+: 
504.2282, Found: 504.2270; [α]D
28 -39.9 (c = 1.0, CHCl3) for (S,S)-4j. 
 




To a clear solution of obtained product (S,S)-4 (ca. 0.41 mmol) in 4.1 mL 
(0.1 M) of THF was added 85.3 μL (1.03 mmol) of 12 M HCl solution. 
Stirring the reaction mixture at ambient temperature for 4 h afforded the 
product as a white precipitate. The solid was filtered and washed with THF to 
afford crude product as the dihydrochloride salt. In the case that the 
precipitate was not detected, 3 ml of distilled water pour into the reaction 
mixture and washed with diethyl ether three times. The aqueous layer was 
concentrated under reduced pressure to afford crude product as a solid. To a 
stirred solution of dihydrochloride salt in 4.1 mL of THF (0.1 M) was added 
342.3 μL (2.46 mmol) of triethylamine (TEA) at ambient temperature. After 
10 min, 272.6 mg (1.23 mmol) of 4-nitrobenzenesulfonyl chloride (4-NsCl) 
was added to the reaction mixture. After stirring at room temperature for 5 h, 
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the reaction mixture was mixed with saturated NaHCO3 and extracted with 
dichloromethane twice. The combined organic layers were dried over 
anhydrous MgSO4, filtered, and concentrated under reduced pressure. The 
residue was separated by column chromatography (Hexane/EtOAc) to afford 
N-Ns protected products as a solid. 
 
Compound (S,S)-8a 
White solid (79% yield), mp 228 ℃, Rf = 0.25 
(Hexane:EtOAc = 2:1), 1H NMR (499 MHz, DMSO-d6): δ 
8.78 (d, J = 9.6 Hz, 1H), 8.26 (d, J = 8.9 Hz, 1H), 8.14 – 
8.08 (m, 2H), 8.08 – 8.01 (m, 2H), 7.89 – 7.82 (m, 2H), 7.77 – 7.70 (m, 2H), 
7.14 – 6.95 (m, 8H), 6.82 (d, J = 7.2 Hz, 2H), 5.83 (d, J = 15.9 Hz, 1H), 5.46 
(dd, J = 15.9, 8.1 Hz, 1H), 4.54 (dd, J = 9.2, 7.2 Hz, 1H), 4.13 – 4.06 (m, 1H); 
13C NMR (126 MHz, DMSO-d6): δ 149.5, 149.4, 147.6, 147.4, 137.9, 136.1, 
133.1, 128.9, 128.8, 128.53, 128.50, 128.45, 128.2, 127.8, 126.5, 125.5, 124.8, 
124.5, 62.0, 61.3; The enantiopurity was confirmed by HPLC analysis 
(Chiralpak®  IA column, 100% Ethyl alcohol + diethyl amine (DEA) 0.1%, 0.3 
ml/min); rac-8a tR = 9.0 min tR = 11.8 min. (S,S)-8a tR = 11.8 min; HRMS 
(ESI) calculated for C28H23O8N4S2 [M-H]
-: 607.0957 , Found: 607.0948; 
[α]D
23 -4.6 (c = 1.0, THF) for (S,S)-8a.   
 
Compound (S,S)-8b 
White solid (86% yield), mp 207 ℃, Rf = 0.23 
(Hexane:EtOAc = 2:1), 1H NMR (499 MHz, DMSO-d6): δ 
8.75 (d, J = 9.7 Hz, 1H), 8.23 (d, J = 9.2 Hz, 1H), 8.13 (d, J 
= 8.7 Hz, 2H), 8.08 (d, J = 8.7 Hz, 2H), 7.84 (d, J = 8.9 Hz, 2H), 7.75 (d, J = 
8.8 Hz, 2H), 7.19 – 7.05 (m, 5H), 6.90 – 6.77 (m, 4H), 5.89 (d, J = 15.9 Hz, 
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1H), 5.50 (dd, J = 15.9, 7.9 Hz, 1H), 4.57 (dd, J = 11.2, 5.1 Hz, 1H), 4.15 – 
4.04 (m, 1H); 13C NMR (75 MHz, DMSO-d6): δ 163.3, 160.1, 149.3, 147.3, 
147.2, 147.01, 146.95, 135.8, 134.10, 134.06, 134.02, 132.9, 130.0, 129.9, 
128.7, 128.6, 128.4, 128.3, 126.3, 125.32, 125.27, 124.6, 124.4, 115.2, 114.9, 
61.1, 61.0, 60.9, 60.8; 19F NMR (282 MHz, DMSO-d6): δ -117.00; The 
enantiopurity was confirmed by HPLC analysis (Chiralpak®  IA column, 100% 
Ethyl alcohol + diethyl amine (DEA) 0.1%, 0.35 ml/min); rac-8b tR = 14.2 
min tR = 17.6 min. (S,S)-8b tR = 17.4 min.; HRMS (ESI) calculated for 
C28H22O8N4FS2 [M-H]
-: 625.0863 , Found: 625.0853; [α]D
23 -6.4 (c = 1.0, 
THF) for (S,S)-8b. 
 
Compound (S,S)-8c 
White solid (84% yield), mp 252 ℃, Rf = 0.25 
(Hexane:EtOAc = 2:1), 1H NMR (499 MHz, DMSO-d6): δ 
8.70 (d, J = 9.7 Hz, 1H), 8.20 (d, J = 9.3 Hz, 1H), 8.13 (d, 
J = 8.9 Hz, 2H), 8.07 (d, J = 8.9 Hz, 2H), 7.82 (d, J = 8.9 Hz, 2H), 7.75 (d, J 
= 8.9 Hz, 2H), 7.17 – 7.01 (m, 7H), 6.88 (d, J = 7.8 Hz, 2H), 5.94 (d, J = 15.9 
Hz, 1H), 5.53 (dd, J = 15.9, 7.7 Hz, 1H), 4.58 (dd, J = 9.5, 6.6 Hz, 1H), 4.18 – 
4.07 (m, 1H); 13C NMR (75 MHz, DMSO-d6): δ 148.8, 146.7, 146.4, 136.4, 
135.3, 132.4, 132.1, 129.3, 128.2, 128.0, 127.8, 127.8, 127.7, 125.9, 125.0, 
124.1, 124.0, 60.4; The enantiopurity was confirmed by HPLC analysis 
(Chiralpak®  IA column, 100% Ethyl alcohol + diethyl amine (DEA) 0.1%, 
0.35 ml/min); rac-8c tR = 14.2 min tR = 17.6 min. (S,S)-8c tR = 17.4 min.; 
HRMS (ESI) calculated for C28H22O8N4ClS2 [M-H]
-: 641.0568, Found: 
641.0563; [α]D






White solid (84% yield), mp 246 ℃, Rf = 0.18 
(Hexane:EtOAc = 2:1), 1H NMR (499 MHz, DMSO-d6): δ 
8.98 (d, J = 9.2 Hz, 1H), 8.51 (d, J = 8.9 Hz, 1H), 8.08 (d, J 
= 8.9 Hz, 2H), 8.04 (d, J = 8.9 Hz, 2H), 7.87 (d, J = 8.8 Hz, 2H), 7.71 (d, J = 
8.8 Hz, 2H), 7.24 (d, J = 8.0 Hz, 2H), 7.09 – 7.04 (m, 3H), 6.98 (t, J = 7.6 Hz, 
1H), 6.85 (t, J = 7.7 Hz, 1H), 6.78 – 6.70 (m, 2H), 5.69 (d, J = 15.9 Hz, 1H), 
5.45 (dd, J = 15.9, 8.7 Hz, 1H), 5.02 – 4.91 (m, 1H), 4.09 – 3.97 (m, 1H); 13C 
NMR (75 MHz, DMSO-d6): δ 149.3, 149.2, 147.5, 146.7, 137.2, 135.6, 133.2, 
132.4, 129.6, 129.4, 128.6, 128.3, 128.2, 128.1, 126.2, 124.6, 124.3, 123.6, 
61.0, 59.9; The enantiopurity was confirmed by HPLC analysis (Chiralpak®  
IA column, 100% Ethyl alcohol + diethyl amine (DEA) 0.1%, 0.35 ml/min); 
rac-8d tR = 15.2 min tR = 16.5 min. (S,S)-8d tR = 16.5 min.; HRMS (ESI) 
calculated C28H22O8N4BrS2 [M-H]
-: 685.0062 , Found: 685.0067; [α]D
23 -
101.1 (c = 1.0, THF) for (S,S)-8d.  
 
Compound (S,S)-8e 
White solid (83% yield), mp 220 ℃, Rf = 0.25 
(Hexane:EtOAc = 2:1), 1H NMR (499 MHz, DMSO-d6): δ 
8.68 (d, J = 9.8 Hz, 1H), 8.23 (d, J = 9.2 Hz, 1H), 8.12 (d, J 
= 8.8 Hz, 2H), 8.07 (d, J = 8.9 Hz, 2H), 7.83 (d, J = 8.8 Hz, 
2H), 7.74 (d, J = 8.8 Hz, 2H), 7.18 – 7.08 (m, 6H), 7.03 (t, J = 7.8 Hz, 1H), 
6.91 – 6.83 (m, 2H), 5.94 (d, J = 15.9 Hz, 1H), 5.53 (dd, J = 15.9, 7.9 Hz, 1H), 
4.55 (dd, J = 9.5, 6.7 Hz, 1H), 4.17 – 4.06 (m, 1H); 13C NMR (75 MHz, 
DMSO-d6): δ 148.8, 146.7, 146.3, 139.8, 135.3, 132.5, 130.0, 128.2, 127.9, 
127.8, 127.7, 126.9, 125.9, 124.9, 124.1, 123.9, 121.3, 60.6, 60.3; The 
enantiopurity was confirmed by HPLC analysis (Chiralpak®  IA column, 100% 
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Ethyl alcohol + diethyl amine (DEA) 0.1%, 0.3 ml/min); rac-8e tR = 12.7 min 
tR = 14.7 min. (S,S)-8e tR = 14.5 min.; HRMS (ESI) calculated 
C28H22O8N4BrS2 [M-H]
-: 685.0062 , Found: 685.0057; [α]D
23 -11.2 (c = 1.0, 
THF) for (S,S)-8e. 
 
Compound (S,S)-8f 
White solid (91% yield), mp 249 ℃, Rf = 0.25 
(Hexane:EtOAc = 2:1), 1H NMR (499 MHz, DMSO-d6): δ 
8.69 (d, J = 9.7 Hz, 1H), 8.20 (d, J = 9.2 Hz, 1H), 8.13 (d, 
J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 7.82 (d, J = 8.7 Hz, 2H), 7.74 (d, J 
= 8.8 Hz, 2H), 7.16 (dd, J = 22.3, 7.4 Hz, 5H), 7.01 (d, J = 8.3 Hz, 2H), 6.88 
(d, J = 7.6 Hz, 2H), 5.94 (d, J = 15.9 Hz, 1H), 5.53 (dd, J = 15.9, 7.7 Hz, 1H), 
4.56 (dd, J = 9.4, 6.7 Hz, 1H), 4.17 – 4.07 (m, 1H); 13C NMR (75 MHz, 
DMSO-d6): δ 149.3, 149.2, 147.2, 146.9, 137.3, 135.7, 132.9, 131.1, 130.1, 
128.7, 128.5, 128.4, 128.3, 126.4, 125.5, 124.6, 124.5, 121.1, 61.0, 60.8; The 
enantiopurity was confirmed by HPLC analysis (Chiralpak®  IA column, 100% 
Ethyl alcohol + diethyl amine(DEA) 0.1%, 0.2 ml/min); rac-8f tR = 25.2 min 
tR = 30.0 min. (S,S)-8f tR = 30.0 min.; HRMS (ESI) calculated 
C28H22O8N4BrS2 [M-H]
-: 685.0062, Found: 685.0056: [α]D
23 +23.2 (c = 1.0, 
THF) for (S,S)-8f. 
 
Compound (S,S)-8g 
 Yellow solid (76% yield), mp 229 ℃ , Rf = 0.23 
(Hexane:EtOAc = 2:1), 1H NMR (499 MHz, DMSO-d6): δ 
8.93 (s, 1H), 8.35 (s, 1H), 8.05 (d, J = 8.6 Hz, 1H), 7.97 (d, J 
= 7.9 Hz, 2H), 7.79 (d, J = 8.0 Hz, 2H), 7.69 (dd, J = 22.9, 
8.1 Hz, 3H), 7.55 (dd, J = 12.9, 7.9 Hz, 4H), 7.42 (dd, J = 17.5, 7.6 Hz, 2H), 
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7.21 (t, J = 7.7 Hz, 1H), 7.05 (s, 3H), 6.70 (s, 2H), 5.91 (d, J = 15.5 Hz, 1H), 
5.62 (s, 1H), 5.41 (s, 1H), 4.28 (s, 1H); 13C NMR (126 MHz, DMSO-d6): δ 
149.3, 149.2, 147.1, 146.9, 136.0, 134.4, 133.4, 130.9, 129.0, 128.8, 128.5, 
128.4, 128.2, 127.1, 126.4, 126.2, 125.9, 125.7, 124.6, 124.1, 123.2, 60.9, 
60.5; The enantiopurity was confirmed by HPLC analysis (Chiralpak®  IA 
column, 100% Ethyl alcohol + diethyl amine (DEA) 0.1 %, 0.4 ml/min); rac-
8g tR = 12.1 min tR = 15.6 min. (S,S)-8g tR = 15.2 min.; HRMS (ESI) 
calculated C32H25O8N4S2 [M-H]
-: 657.1114, Found: 657.1107; [α]D
23 -49.5 (c 
= 1.0, THF) for (S,S)-8g. 
 
Compound (S,S)-8h 
 White solid (74% yield), mp 186 ℃, Rf = 0.08 
(Hexane:EtOAc = 2:1), 1H NMR (499 MHz, DMSO-d6): δ 
8.67 (d, J = 9.7 Hz, 1H), 8.26 – 8.20 (m, 2H), 8.11 (d, J = 
8.8 Hz, 2H), 8.06 (d, J = 8.9 Hz, 2H), 7.82 (d, J = 8.9 Hz, 2H), 7.79 (d, J = 8.9 
Hz, 2H), 7.49 (t, J = 7.7 Hz, 1H), 7.18 (d, J = 7.8 Hz, 1H), 7.10 (dd, J = 4.8, 
1.7 Hz, 3H), 7.01 (dd, J = 7.3, 4.9 Hz, 1H), 6.84 – 6.76 (m, 2H), 5.86 (d, J = 
15.9 Hz, 1H), 5.55 (dd, J = 15.9, 7.8 Hz, 1H), 4.64 (dd, J = 9.6, 6.5 Hz, 1H), 
4.35 – 4.28 (m, 1H); 13C NMR (75 MHz, DMSO-d6): δ 156.9, 149.3, 149.2, 
149.0, 147.4, 147.0, 136.8, 135.7, 132.5, 128.6, 128.5, 128.34, 128.25, 126.3, 
125.9, 124.6, 124.4, 122.9, 122.6, 62.7, 60.3; The enantiopurity was 
confirmed by HPLC analysis (Chiralpak®  IA column, 100% Ethyl alcohol + 
diethyl amine (DEA) 0.1%, 0.3 ml/min); rac-8h tR = 18.7 min tR = 19.6 min. 
(S,S)-8h tR = 19.5 min.; HRMS (ESI) calculated for C27H22O8N5S2 [M-H]
-: 
608.0904, Found: 608.0910; [α]D






Yellow solid (76% yield), mp 215 ℃, Rf = 0.18 
(Hexane:EtOAc = 2:1), 1H NMR (499 MHz, DMSO-d6): 
δ 8.63 (d, J = 9.7 Hz, 1H), 8.21 (d, J = 9.1 Hz, 1H), 8.11 
(d, J = 8.3 Hz, 2H), 8.05 (d, J = 8.3 Hz, 2H), 7.83 (d, J = 8.4 Hz, 2H), 7.70 (d, 
J = 8.3 Hz, 2H), 7.16 – 7.08 (m, 3H), 6.92 (d, J = 8.2 Hz, 2H), 6.87 (d, J = 7.3 
Hz, 2H), 6.50 (d, J = 8.2 Hz, 2H), 5.89 (d, J = 15.9 Hz, 1H), 5.51 (dd, J = 15.9, 
7.8 Hz, 1H), 4.49 (dd, J = 9.2, 7.2 Hz, 1H), 4.15 – 4.03 (m, 1H), 3.55 (s, 3H); 
13C NMR (75 MHz, DMSO-d6): δ 158.8, 149.2, 147.4, 147.2, 135.9, 132.7, 
129.6, 129.2, 128.7, 128.5, 128.3, 128.2, 126.3, 125.7, 124.6, 124.3, 113.6, 
61.2, 61.1, 55.3; The enantiopurity was confirmed by HPLC analysis 
(Chiralpak®  IA column, 100 % Ethyl alcohol + diethyl amine (DEA) 0.1 %, 
0.3 ml/min); rac-8i tR = 15.1 min tR = 21.3 min. (S,S)-8i tR = 21.1 min.; HRMS 
(ESI) calculated C29H25O9N4S2 [M-H]
-: 637.1063, Found: 637.1055; [α]D
23 
+4.6 (c = 1.0, THF) for (S,S)-8i. 
 
Compound (S,S)-8j 
 White solid (59% yield), mp 281 ℃, Rf = 0.30 
(Hexane:EtOAc = 1:2), 1H NMR (499 MHz, DMSO-
d6): δ 9.70 (s, 1H), 8.59 (d, J = 9.7 Hz, 1H), 8.19 (d, J 
= 9.1 Hz, 1H), 8.09 (d, J = 8.7 Hz, 2H), 8.03 (d, J = 8.7 
Hz, 2H), 7.79 (d, J = 8.7 Hz, 2H), 7.71 (d, J = 8.7 Hz, 2H), 7.13 (d, J = 7.9 Hz, 
5H), 6.90 (dd, J = 13.8, 7.8 Hz, 4H), 5.93 (d, J = 15.9 Hz, 1H), 5.54 (dd, J = 
15.8, 7.7 Hz, 1H), 4.50 (dd, J = 9.3, 7.1 Hz, 1H), 4.16 – 4.06 (m, 1H), 1.94 (s, 
3H); 13C NMR (75 MHz, DMSO-d6): δ 168.5, 149.2, 147.4, 147.1, 138.9, 
135.9, 132.6, 132.1, 128.7, 128.4, 128.3, 128.2, 128.1, 126.3, 126.0, 124.5, 




664.1172, Found: 664.1161: [α]D
23 +22.0 (c = 1.0, THF) for (S,S)-8j. 
 
Synthesis of Piperazines from N-Nosyl Vicinal Diamines  
 
Compound (S,S)-9a 
N-Nosyl diamine 8a (856 mg, 1.41 mmol) was dissolved into 
anhydrous CH2Cl2 (70.3 mL), stirred at 0 °C under nitrogen 
and treated with DBU (462.6 μL, 3.09 mmol). After 10 min, a 
solution of diphenylvinylsulfonium salt 11 (611 mg, 1.68 
mmol) in CH2Cl2 (5.0 mL) was added dropwise over two min. The reaction 
mixture was further stirred for 4 h and allowed to warm to room temperature. 
The reaction mixture was quenched with sat. ammonium chloride solution and 
extracted with CH2Cl2 twice, dried over anhydrous MgSO4, filtered and 
evaporated under reduced pressure. The residue was then purified using 
column chromatography on silica (Hexane:EtOAc = 4:1). The desired product 
9a was obtained as a white solid (750 mg, 84% yield); Rf = 0.33 
(Hexane:EtOAc = 2:1); mp 306 ℃; 1H NMR (499 MHz, DMSO-d6): δ 8.06 (t, 
J = 9.0 Hz, 4H), 7.98 (d, J = 8.6 Hz, 2H), 7.75 (d, J = 8.5 Hz, 2H), 7.40 (d, J 
= 7.5 Hz, 2H), 7.30 (t, J = 7.4 Hz, 2H), 7.24 (t, J = 7.2 Hz, 1H), 7.16 (s, 3H), 
6.89 (d, J = 4.5 Hz, 2H), 6.40 (d, J = 15.9 Hz, 1H), 5.69 (dd, J = 16.0, 6.1 Hz, 
1H), 5.17 (s, 1H), 5.09 (d, J = 5.9 Hz, 1H), 3.97 (d, J = 13.4 Hz, 1H), 3.69 (d, 
J = 12.5 Hz, 1H), 3.49 (t, J = 10.4 Hz, 1H), 3.39 (t, J = 9.8 Hz, 1H); 13C NMR 
(75 MHz, DMSO-d6): δ 149.8, 149.6, 145.1, 144.2, 137.6, 135.5, 133.5, 129.0, 
128.9, 128.62, 128.59, 127.9, 127.3, 126.5, 125.0, 124.8, 124.6, 61.2, 59.3, 
41.4; HRMS (ESI) calculated C30H25O8N4S2 [M-H]
-: 633.1114, Found: 
633.1106. [α]D





 N-Nosyl diamine 8f (857 mg, 1.25 mmol) was dissolved 
into anhydrous CH2Cl2 (62.3 mL), stirred at 0 °C under 
nitrogen and treated with DBU (410.1 μL, 2.74 mmol). After 
10 min, a solution of diphenylvinylsulfonium salt 11 (542 
mg, 1.50 mmol) in CH2Cl2 (4.5 mL) was added dropwise over two min. The 
reaction mixture was further stirred for 4 h and allowed to warm to room 
temperature. The reaction mixture was quenched with sat. ammonium 
chloride solution and extracted with CH2Cl2 twice, dried over anhydrous 
MgSO4, filtered and evaporated under reduced pressure. The residue was then 
purified using column chromatography on silica (Hexane:EtOAc = 4:1). The 
desired product 9f was obtained as a white solid (790 mg, 89% yield); Rf = 
0.30 (Hexane:EtOAc = 2:1); mp 274 ℃; 1H NMR (499 MHz, DMSO-d6): δ 
8.12 (d, J = 8.8 Hz, 2H), 8.06 (d, J = 8.9 Hz, 2H), 7.99 (d, J = 8.9 Hz, 2H), 
7.76 (d, J = 8.8 Hz, 2H), 7.44 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.5 Hz, 2H), 
7.19 – 7.13 (m, 3H), 6.90 (dd, J = 6.5, 2.8 Hz, 2H), 6.41 (d, J = 15.8 Hz, 1H), 
5.71 (dd, J = 16.0, 5.7 Hz, 1H), 5.16 (s, 1H), 5.01 (d, J = 5.7 Hz, 1H), 3.93 (dt, 
J = 12.7, 3.9 Hz, 1H), 3.70 (dt, J = 8.4, 3.9 Hz, 1H), 3.62 – 3.52 (m, 1H), 3.51 
– 3.44 (m, 1H); 13C NMR (75 MHz, DMSO-d6): δ 149.2, 149.1, 144.1, 143.7, 
136.70, 135.0, 132.8, 131.2, 128.9, 128.4, 128.13, 128.07, 126.0, 124.8, 124.5, 
124.3, 120.9, 60.3, 59.1, 41.1, 40.5; HRMS (ESI) calculated C30H24O8N4BrS2 
[M-H]-: 711.0219, Found: 711.0204; [α]D









 N-Nosyl piperazine 9a (73.1 mg, 0.115 mmol), CH3CN (1.2 
mL), CCl4 (1.2 mL), H2O (1.8 mL) and NaIO4 (197.1 mg, 0.922 
mmol) was stirred to a uniform suspension. RuCl3·H2O (0.72 
mg, 0.00346 mmol) was added, and the reaction was stirred for 
2 days at ambient temperature. The reaction was quenched with 2 M HCl (8 
mL) and then extracted with EtOAc three times. The organic layers were 
filtered through a Celite, dried over anhydrous MgSO4 and concentrated under 
reduced pressure. The residue was then purified using column 
chromatography on silica (Hexane:EtOAc:AcOH = 3:1:0.01). The desired 
product 10a was obtained as a white solid (49 mg, 74% yield); Rf = 0.33 
(Hexane:EtOAc:AcOH = 3:1:0.01); mp 208 ℃; 1H NMR (499 MHz, 
Acetone-d6): δ 8.30 (d, J = 8.5 Hz, 2H), 8.24 (d, J = 8.5 Hz, 2H), 8.07 (d, J = 
8.5 Hz, 2H), 7.89 (d, J = 8.5 Hz, 2H), 7.50 (d, J = 7.2 Hz, 2H), 7.41 – 7.29 (m, 
3H), 5.85 (s, 1H), 5.23 (s, 1H), 3.99 (d, J = 10.9 Hz, 1H), 3.85 (d, J = 9.6 Hz, 
1H), 3.50 – 3.36 (m, 2H); 13C NMR (75 MHz, Acetone-d6): δ 169.1, 150.11, 
150.05, 145.7, 145.0, 136.3, 128.8, 128.6, 128.5, 128.0, 127.2, 124.4, 124.2, 
58.9, 57.8, 41.4, 40.7; HRMS (ESI) calculated C23H19O10N4S2 [M-H]
-: 
575.0543, Found: 575.0537; [α]D






N-Nosyl piperazine 9f (125 mg, 0.175 mmol), CH3CN (2.0 
mL), CCl4 (2.0 mL), H2O (3.0 mL) and NaIO4 (300 mg, 1.4 
mmol) was stirred to a uniform suspension. RuCl3·H2O (1.1 
mg, 0.0053 mmol) was added, and the reaction was stirred 
for 2 days at ambient temperature. The reaction was quenched with 2 M HCl 
(14 mL) and then the reaction mixture was extracted with EtOAc (15 mL) 
three times from aqueous phase. The organic layers were filtered through a 
Celite, dried over anhydrous MgSO4 and concentrated under reduced pressure. 
The residue was then purified using column chromatography on silica 
(Hexane:EtOAc:AcOH = 3:1:0.01). The desired product 10f was obtained as a 
white solid (82.1 mg, 72% yield); Rf = 0.33 (Hexane:EtOAc:AcOH = 
3:1:0.01); mp 258 ℃; 1H NMR (499 MHz, Acetone-d6): δ 8.30 – 8.19 (m, 
4H), 8.08 (d, J = 8.5 Hz, 2H), 7.90 (d, J = 8.5 Hz, 2H), 7.55 (d, J = 7.9 Hz, 
2H), 7.48 (d, J = 7.6 Hz, 2H), 5.88 (s, 1H), 5.18 (s, 1H), 3.92 (d, J = 12.8 Hz, 
1H), 3.84 (d, J = 11.7 Hz, 1H), 3.50 – 3.31 (m, 2H); 13C NMR (126 MHz, 
Acetone-d6): δ 169.4, 150.3, 150.2, 145.7, 145.3, 136.4, 132.0, 129.6, 129.0, 
128.8, 124.7, 124.2, 121.8, 59.3, 57.7, 41.6, 40.9; HRMS (ESI) calculated 
C23H18O10N4BrS2 [M-H]
-: 652.9648, Found: 652.9644; [α]D
23 +8.6 (c = 1.0, 




















γ,δ-Diamino acid functionality is a core structure often embedded in 
physiologically active molecules (Figure II-1). This moiety has been found as 
useful intermediates for the preparation of therapeutic agents such as selective 
nonpeptide substance P receptor antagonists (CP-96,345 and CP-99,994),1 
dipeptidyl peptidase IV (DDP4) inhibitor (SYR-322),2 potent factor Xa 
inhibitor,3 potent nootropic drug (Unifiram, DM 232)4 and antiviral agents 
(Oseltamivir (1), Zanamivir (2)).5 In particular, with a possible avian flu6 or 
swine flu7 pandemic, the synthetic challenge of oseltamivir8 together have 
recently attracted considerable interest in developing efficient methods for 
making the antiviral agent.9 Elegant methods for making analogs of the 
antiviral agent would be useful for combating drug resistance.10 
 
 
Figure II-1. Compounds Containing γ,δ-Diamino Acid Core 
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We have previously shown that diaza-Cope rearrangement (DCR) can be 
used to prepare a wide variety of aryl and alkyl substituted chiral vicinal 
diamines as well as non-symmetrically substituted chiral vicinal diamines.11 
Here we report stereospecific synthesis of γ,δ-diamino esters by using the 
rearrangement reaction.. 
 
II-2. Result and Discussion 
 
For the synthesis of 3a to 3d, 1 equiv of the corresponding aryl aldehyde is 
allowed to react with (R,R)-1,2-bis(2-hydroxyphenyl)-1,2-diaminoethane 
(hpen, 0.15 mmol) in DMSO (0.3 M, 0.5 mL) at ambient temperature for 1 h 
to form the imidazolidine intermediate, which was confirmed from 1H NMR 
spectra of the reaction mixture in DMSO-d6 (Scheme II-1). Ethyl trans-4-oxo-
2-butenoate (0.17 mmol) is then added to the reaction mixture and stirred at 
ambient temperature for 2 h for the diaza-Cope rearrangement (DCR).11 
 
 
Scheme II-1. Stereospecific Synthesis of γ,δ-Diimino Ester Derivatives. 
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In case of the alkyl substituted diimines (3e to 3g), toluene was used instead 
of DMSO as a solvent. The diaza-Cope rearrangement required 1 h of heating 
at 110 °C. The crude products (3a to 3g) were purified by flash 
chromatography. 
Figure II-2 shows the crystal structure of the product diimine (3d) formed 
from the reaction of (R,R)-hpen and 2,6-dichlorobenzaldehyde. The diaza-
Cope rearrangement reaction gives the product diimine in S,S configuration as 
expected from the chair-like six-membered ring transition state with all 




Figure II-2. Crystal Structure of Diimine 3d.  
 
Table II-1 shows that the rearrangement reaction takes place with good yield 
and excellent stereospecificity for diimines containing aryl substituent (entries 
1-4). Most aryl aldehydes smoothly formed the imidazolidine intermediates. 
The aldehyde containing ortho-substituents (3d) takes about 2 h to form the 
imidazolidine intermediate due to steric hindrance. In case of diimines 
containing alkyl substituent, the rearrangement reaction gives the product 
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diimines in moderate yield and excellent stereospecificity (entries 5 to 7). 
Thus a wide variety of alkyl and aryl substituted γ,δ-diamino ester derivatives 
can be synthesized stereosepecifically in a one-pot reaction by using the 
diaza-Cope rearrangement. 
 




Entry R Solvent Temp.b Yield(%)c Ee(%)d 
1 
 
DMSO RT(1)/RT(2)  74 >99 
2 
 
DMSO RT(1)/RT(2) 80 >99 
3 
 
DMSO RT(1)/RT(2) 79 >99 
4 
 




      
Toluene RT(1)/110(1) 62 >99 
6 
 
Toluene RT(1)/110(1) 53 >99 
7e 
 
Toluenef RT(2)/110(1) 50 >99 
 
a Reaction conditions. i) (R,R)-hpen (0.15 mmol), aldehyde (0.15 mmol), solvent 
(0.3 M) ii) Ethyl trans-4-oxo-2-butenoate (0.17 mmol).  
b Reaction time is in round bracket. 
c Yield of isolated products.  
d Ee was determined by chiral HPLC analysis using Chiralpak®  IA column.  
e The absolute configuration of obtained product is (S,R)-form. 
f Toluene (0.1 M) was used for the reaction.  
 
 
Aryl12 and alkyl13 aldehydes as well as trans-cinnamaldehyde 14 can be used 
to make diamines via the diaza-Cope rearrangement. The aldehyde conjugated 
to ester is more reactive than benzaldehyde or trans-cinnamaldehyde for the 
rearrangement reaction. DFT computation (B3LYP at 6-31G* level) shows 
that the energy barrier for the rearrangement is the lowest for 4z (Scheme II-
2), which bodes well with the experimental observation. Electron deficient 
aldehydes are generally more reactive than electron rich ones towards the 
DCR.11f In addition, the aldehyde conjugated to ester that is used to make 4z 
is not only less sterically hindered because of the different size between 
phenyl group in benzaldehyde and olefin group, but also more reactive 
because of electronic difference between the ester and phenyl groups in trans-
cinnamaldehyde for the rearrangement reaction.  
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Alkyl aldehydes are found to be less reactive than aryl aldehydes for diaza-
Cope rearrangement. Chin’s group previously showed that there is an energy 
difference of 5.4 kcal/mol between the transition states of diphenyl-substituted 
diimine and diisopropyl-substituted one.13 Thus, it required harsher conditions 
to prepare dialkyl substituted products while the preparation of diaryl 




Scheme II-2. Calculated Activation Enthalpies for the DCR.15 
 
In the same context, the synthesis of 3e-3g required higher temperature than 
that of 3a-3d, even though the half of substituents on diimine was derived 
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from ethyl trans-4-oxo-2-butenoate. Moreover, we realized the use of ethyl 
trans-4-oxo-2-butenoate led to shorter reaction time compared to previous 
work.13 Also DFT computation shows that the energy barriers for formation of 
3a-3d are lower than those for formation of 3e-3g, which is in good 




Scheme II-3. Energy profile for the DCR Process of Aryl and Alkyl Diimines 





Scheme II-4. Hydrolysis of Diimines. 
 
Hydrolysis of diimines 3c, 3e, and 3f was carried out with concentrated HCl 
in THF as previously reported.12 The reaction gave the corresponding chiral 
γ,δ-diamino ester dihydrochlorides as precipitates in 85%, 87% and 88% 




In summary, we have shown that ethyl trans-4-oxo-2-butenoate can be used 
for the preparation of a variety of γ,δ-diimino esters by the diaza-Cope 
rearrangement followed by hydrolysis of the diimines. Both DFT computation 
and experimental results show that this conjugated aldehyde is more reactive 
than other aromatic or aliphatic aldehydes for the rearrangement reaction. In 
addition, it was found that the diimines with aryl substituents rearrange more 








II-4. Experimental  
 
General Information.  
 
Commercially available compounds were used without further purification 
or drying. The 1H NMR and 13C NMR spectra were recorded on a Varian 
Mercury 400 spectrometer or a Bruker Advance III spectrometer operating at 
400 MHz. High resolution mass spectra (HRMS) were obtained on an 
ABI/Sciex QStar Mass Spectrometer (ESI) at Advanced Instrumentation for 
Molecular Structure (AIMS) at the University of Toronto and on a 
ThermoFinnigan LCQ™ Classic, Quadrupole Ion-Trap Mass Spectrometer at 
Seoul National University. Optical rotation was obtained at 589 nm using a 
Rudolph Autopol IV polarimeter at the University of Toronto and on a 
JASCO P-1030 automatic polarimeter at Seoul National University. Melting 
points were recorded using an Electrothermal IA 9100 digital melting point 
apparatus. Reactions were monitored using 1H NMR spectroscopy. 
Chromatography was performed on Silicycle 230-400 mesh silica gel and 
thin-layer chromatography (TLC) was performed on EMD Silica Gel 60 F254 
plates. Visualization of the developed plates was performed under UV light 
(254 nm). HPLC analysis was performed on a Hewlett-Packard 1100 Series 
HPLC, UV detection monitored at 254.4 nm using a Chiralpak®  IA column 








Preparation of γ,δ-diimino ester derivatives.  
 
Compound (S,S)-3a  
To a stirred solution of 36.6 mg (0.15 mmol) of 
(R,R)-hpen in 0.5 mL of DMSO (0.3 M) was 
added 4-fluorobenzaldehyde (0.15 mmol). The 
resulting solution was stirred for 1 h at room 
temperature. The formation of imidazolidine was confirmed by taking 1H 
NMR spectra of the reaction mixture in DMSO-d6. 20 µL of ethyl trans-4-
oxo-2-butenoate (0.17 mmol) was added to the reaction mixture in one portion. 
After stirring at room temperature for 2 h, the reaction mixture was mixed 
with distilled water (30 mL) and extracted with diethyl ether. The combined 
organic layers were washed with brine/water (1:1) three times and dried over 
anhydrous MgSO4, filtered, and concentrated under reduced pressure. 
Purification by flash column chromatography on silica gel eluting with ethyl 
acetate / n-hexanes (15 %) gave the desired product. Yellow solid (74 % 
yield); mp 82-83 oC, Rf = 0.25 (n-Hexane:EtOAc = 4:1); 
1H NMR (400 MHz, 
CDCl3): δ 12.91 (s, 1H), 12.75 (s, 1H), 8.34 (s, 1H), 8.25 (s, 1H), 7.40 – 7.27 
(m, 4H), 7.21 – 7.14 (m, 2H), 7.07 (t, J = 8.7 Hz, 2H), 6.98 – 6.79 (m, 6H), 
5.86 (dd, J = 15.7, 1.5 Hz, 1H), 4.57 (d, J = 7.3 Hz, 1H), 4.38 – 4.30 (m, 1H), 
4.14 (q, J = 7.1 Hz, 2H) 1.24 (t, J = 7.1 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): 
δ 167.60, 166.75, 165.77, 161.01, 160.96, 144.33, 134.84, 134.80, 133.22, 
133.07, 132.13, 132.07, 129.57, 129.49, 123.96, 119.12, 119.09, 118.50, 
118.44, 117.21, 117.10, 116.18, 115.96, 77.21, 75.99, 60.77, 14.29; 19F NMR 
(377 MHz, CDCl3): δ -113.44; The enantiopurity was confirmed by HPLC 
analysis (Chiralpak®  IA column, n-Hexane : EtOH = 7:3, 1.0 ml/min), Rac-3a 
tR= 13.412 min, tR = 35.636 min, (S,S)-3a tR= 13.316 min; []D
27 +52.5 (c = 
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Compound (S,S)-3b  
To a stirred solution of 36.6 mg (0.15 mmol) of 
(R,R)-hpen in 0.5 mL of DMSO (0.3 M) was 
added 4-cyanobenzaldehyde (0.15 mmol). The 
resulting solution was stirred for 1 h at room 
temperature. The formation of imidazolidine was confirmed by taking 1H 
NMR spectra of the reaction mixture in DMSO-d6. 20 µL of ethyl trans-4-
oxo-2-butenoate (0.17 mmol) was added to the reaction mixture in one portion. 
After stirring at room temperature for 2 h, the reaction mixture was mixed 
with distilled water (30 mL) and extracted with diethyl ether. The combined 
organic layers were washed with brine/water (1:1) three times and dried over 
anhydrous MgSO4, filtered, and concentrated under reduced pressure. 
Purification by flash column chromatography on silica gel eluting with ethyl 
acetate / n-hexanes (20 %)  gave the desired product. Yellow solid (80 % 
yield), mp 100-101 oC, Rf = 0.33 (n-Hexane:EtOAc = 2:1); 
1H NMR (400 
MHz, CDCl3): δ 12.69 (s, 1H), 12.60 (s, 1H), 8.37 (s, 1H), 8.25 (s, 1H), 7.68 
(d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.2 Hz, 2H), 7.36 – 7.27 (m, 2H), 7.21 – 7.14 
(m, 2H), 6.99 – 6.93 (m, 2H), 6.91 – 6.81 (m, 3H), 5.85 (dd, J = 15.7, 1.5 Hz, 
1H), 4.64 (d, J = 6.9 Hz, 1H), 4.40 – 4.31 (m, 1H), 4.15 (q, J = 7.1 Hz, 2H), 
1.24 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 167.94, 167.59, 
165.56, 160.98, 160.94, 144.18, 143.53, 133.47, 133.46, 132.83, 132.25, 
132.21, 128.76, 124.53, 119.28, 119.24, 118.49, 118.32, 118.31, 117.28, 
117.21, 112.45, 77.61, 75.65, 60.91, 14.28; The enantiopurity was confirmed 
by HPLC analysis (Chiralpak®  IA column, n-Hexane:EtOH = 7:3, 1.0 ml/min), 




+3.55 (c = 1.0, CHCl3); HRMS (ESI) calculated for C28H26N3O4 [M+H]
+: 
468.1923, Found: 468.1917. 
 
Compound (S,S)-3c  
To a stirred solution of 36.6 mg (0.15 mmol) of 
(R,R)-hpen in 0.5 mL of DMSO (0.3 M) was 
added 2-furaldehyde (0.15 mmol). The resulting 
solution was stirred for 1 h at room temperature. 
The formation of imidazolidine was confirmed by taking 1H NMR spectra of 
the reaction mixture in DMSO-d6. 20 µL of ethyl trans-4-oxo-2-butenoate 
(0.17 mmol) was added to the reaction mixture in one portion. After stirring at 
room temperature for 2 h, the reaction mixture was mixed with distilled water 
(30 mL) and extracted with diethyl ether. The combined organic layers were 
washed with brine/water (1:1) three times and dried over anhydrous MgSO4, 
filtered, and concentrated under reduced pressure. Purification by flash 
column chromatography on silica gel eluting with ethyl acetate / n-hexanes 
(15 %) gave the desired product. Yellow oil (79% yield), Rf = 0.31 (n-
Hexane:EtOAc = 4:1); 1H NMR (400 MHz, CDCl3): δ 12.79 (s, 1H), 12.74 (s, 
1H), 8.31 (s, 1H), 8.30 (s, 1H), 7.44 (dd, J = 1.8, 0.8 Hz, 1H), 7.34 – 7.25 (m, 
2H), 7.23 – 7.16 (m,z 2H), 7.02 – 6.90 (m, 3H), 6.88 – 6.80 (m, 2H), 6.39 – 
6.29 (m, 2H), 5.94 (dd, J = 15.7, 1.5 Hz, 1H), 4.76 (d, J = 7.4 Hz, 1H), 4.62 – 
4.51 (m, 1H), 4.16 (q, J = 7.1 Hz, 2H), 1.25 (t, J = 7.1 Hz, 3H); 13C NMR 
(100 MHz, CDCl3): δ 167.73, 167.27, 165.88, 161.05, 161.04, 151.20, 144.25, 
142.95, 133.17, 133.07, 132.14, 132.13, 123.92, 119.06, 118.96, 118.52, 
118.51, 117.22, 117.19, 110.67, 109.11, 73.38, 70.35, 60.76, 14.30; The 
enantiopurity was confirmed by HPLC analysis (Chiralpak®  IA column, n-
Hexane:EtOH = 7:3, 1.0 ml/min), Rac-3c tR= 9.867 min, tR = 29.024 min, 
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(S,S)-3c tR= 9.820 min; []D
27 +82.7 (c = 1.0, CHCl3); HRMS (ESI) calculated 
for C25H25N2O5 [M+H]
+: 433.1763, Found: 433.1757. 
 
Compound (S,S)-3d  
To a stirred solution of 36.6 mg (0.15 mmol) of 
(R,R)-hpen in 0.5 mL of DMSO (0.3 M) was 
added 2,6-dichlorobenzaldehyde (0.15 mmol). The 
resulting solution was stirred for 2 h at room 
temperature. The formation of imidazolidine was confirmed by taking 1H 
NMR spectra of the reaction mixture in DMSO-d6. 20 µL of ethyl trans-4-
oxo-2-butenoate (0.17 mmol) was added to the reaction mixture in one portion. 
After stirring at room temperature for 2 h, the reaction mixture was mixed 
with distilled water (30 mL) and extracted with diethyl ether. The combined 
organic layers were washed with brine/water (1:1) three times and dried over 
anhydrous MgSO4, filtered, and concentrated under reduced pressure. 
Purification by flash column chromatography on silica gel eluting with ethyl 
acetate / n-hexanes (15 %) gave the desired product. Yellow solid (78 % 
yield), mp 98-100 oC, Rf = 0.37 (n-Hexane:EtOAc = 4:1); 
1H NMR (400 MHz, 
CDCl3): δ 13.00 (s, 1H), 12.79 (s, 1H), 8.38 (s, 1H), 8.34 (s, 1H), 7.38 (d, J = 
8.0 Hz, 2H), 7.33 – 7.14 (m, 5H), 6.97 – 6.76 (m, 5H), 5.94 (dd, J = 15.7, 1.2 
Hz, 1H), 5.57 (d, J = 9.3 Hz, 1H), 5.26 – 5.19 (m, 1H), 4.12 (qd, J = 7.1, 1.2 
Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 168.14, 
167.97, 165.70, 160.98, 160.83, 143.50, 133.57, 133.21, 133.12, 132.27, 
132.23, 130.89, 130.07, 129.13, 123.85, 119.17, 118.98, 118.55, 118.51, 
117.11, 117.05, 73.12, 71.74, 60.70, 14.26; The enantiopurity was confirmed 
by HPLC analysis (Chiralpak®  IA column, n-Hexane:EtOH = 7:3, 1.0 ml/min), 




+60.2 (c = 1.0, CHCl3); HRMS (ESI) calculated for C27H25Cl2N2O4 [M+H]
+: 
511.1191 , Found: 511.1167. 
 
Compound (S,S)-3e  
To a stirred solution of 36.6 mg (0.15 mmol) of 
(R,R)-hpen in 0.5 mL of toluene (0.3 M) was 
added isobutyraldehyde (0.15 mmol). The 
resulting solution was stirred for 1 h at room 
temperature. The formation of imidazolidine was confirmed by taking 1H 
NMR spectra of the reaction mixture in DMSO-d6. 20 µL of ethyl-trans-4-
oxo-2-butenoate (0.17 mmol) was added to the reaction mixture in one portion. 
After refluxing at 110 o C for 1 h, the reaction mixture was concentrated under 
reduced pressure. Purification by flash column chromatography on silica gel 
eluting with ethyl acetate / n-hexanes (15 %) gave the desired product. Yellow 
oil (62 % yield), Rf = 0.32 (n-Hexane:EtOAc = 4:1); 
1H NMR (400 MHz, 
CDCl3): δ 13.17 (s, 1H), 12.84 (s, 1H), 8.23 (s, 1H), 8.21 (s, 1H), 7.31 – 7.24 
(m, 2H), 7.17 (ddd, J = 14.5, 7.7, 1.7 Hz, 2H), 7.09 (dd, J = 15.7, 7.2 Hz, 1H), 
6.93 (dd, J = 8.3, 0.5 Hz, 2H), 6.85 – 6.78 (m, 2H), 6.05 (dd, J = 15.7, 1.2 Hz, 
1H), 4.27 – 4.17 (m, 3H), 3.27 (dd, J = 7.4, 3.9 Hz, 1H), 2.19 – 2.07 (m, 1H), 
1.28 (t, J = 7.1 Hz, 3H), 1.05 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 166.85, 166.72, 165.97, 161.19, 160.98, 145.01, 
132.95, 132.64, 131.94, 131.84, 123.81, 118.97, 118.80, 118.51, 118.46, 
117.12, 117.03, 78.63, 72.51, 60.85, 29.42, 20.80, 16.84, 14.33; The 
enantiopurity was confirmed by HPLC analysis (Chiralpak®  IA column, n-
Hexane:EtOH = 7:3, 1.0 ml/min), Rac-3e tR= 6.167 min, tR = 9.981 min, 
(S,S)-3e tR= 6.154 min; []D
27 +109.6 (c = 1.0, CHCl3); HRMS (ESI) 
calculated for C24H29N2O4 [M+H]





 To a stirred solution of 36.6 mg (0.15 mmol) of 
(R,R)-hpen in 0.5 mL of toluene (0.3 M) was 
added cyclohexanecarboxaldehyde (0.15 mmol). 
The resulting solution was stirred for 1 h at room 
temperature. The formation of imidazolidine was confirmed by taking 1H 
NMR spectra of the reaction mixture in DMSO-d6. 20 µL of ethyl-trans-4-
oxo-2-butenoate (0.17 mmol) was added to the reaction mixture in one portion. 
After refluxing at 110 oC for 1 h, the reaction mixture was concentrated under 
reduced pressure. Purification by flash column chromatography on silica gel 
eluting with ethyl acetate / n-hexanes (15 %) gave the desired product. Light 
yellow solid (53% yield), 147-148 oC, Rf = 0.4 (n-Hexane:EtOAc = 4:1); 
1H 
NMR (400 MHz, CDCl3): δ 13.23 (s, 1H), 12.87 (s, 1H), 8.23 (s, 1H), 8.18 (s, 
1H), 7.31 – 7.23 (m, 2H), 7.20 – 7.13 (m, 2H), 7.09 (dd, J = 15.7, 7.0 Hz, 1H), 
6.93 (d, J = 8.3 Hz, 2H), 6.84 – 6.78 (m, 2H), 6.03 (dd, J = 15.7, 1.2 Hz, 1H), 
4.31 (td, J = 7.1, 0.9 Hz, 1H), 4.20 (q, J = 7.1 Hz, 2H), 3.25 (dd, J = 7.2, 4.1 
Hz, 1H), 1.88 – 1.69 (m, 4H), 1.68 – 1.53 (m, 3H), 1.28 (t, J = 7.1 Hz, 3H), 
1.25 – 1.18 (m, 2H), 1.13 – 0.98 (m, 2H); 13C NMR (100 MHz, CDCl3): δ 
166.83, 166.38, 166.02, 161.22, 161.00, 145.23, 132.92, 132.60, 131.92, 
131.79, 123.70, 118.94, 118.77, 118.52, 118.44, 117.13, 117.05, 78.42, 71.71, 
60.83, 39.14, 31.14, 27.67, 26.26, 26.26, 26.16, 14.31; The enantiopurity was 
confirmed by HPLC analysis (Chiralpak®  IA column, n-Hexane:EtOH = 7:3, 
1.0 ml/min), Rac-3f tR= 6.707 min, tR = 25.127 min, (S,S)-3f tR= 6.711 min; 
[]D
27 +58.8 (c = 1.0, CHCl3); HRMS (ESI) calculated for C27H33N2O4 







 To a stirred solution of 36.6 mg (0.15 mmol) of 
(R,R)-hpen in 1.5 mL of toluene (0.1 M) was 
added (R)-(+)-2,2-dimethyl-1,3-dioxolane-4-
carboxaldehyde (0.15 mmol). The resulting 
solution was stirred for 2 h at room temperature. The formation of 
imidazolidine was confirmed by taking 1H NMR spectra of the reaction 
mixture in DMSO-d6. 20 µL of ethyl-trans-4-oxo-2-butenoate (0.17 mmol) 
was added to the reaction mixture in one portion. After refluxing at 110 oC for 
1 h, the reaction mixture was concentrated under reduced pressure. 
Purification by flash column chromatography on silica gel eluting with ethyl 
acetate / n-hexanes (20 %) gave the desired product. Yellow oil (50 % yield), 
Rf = 0.17 (n-Hexane:EtOAc = 4:1); 
1H NMR (400 MHz, CDCl3) δ 13.00 (s, 
1H), 12.76 (s, 1H), 8.26 (d, J = 10.4 Hz, 2H), 7.34 – 7.25 (m, 2H), 7.21 – 7.13 
(m, 3H), 6.98 – 6.91 (m, 2H), 6.86 – 6.78 (m, 2H), 6.11 (dd, J = 15.7, 1.3 Hz, 
1H), 4.43 (td, J = 6.7, 4.0 Hz, 1H), 4.37 (td, J = 6.9, 1.0 Hz, 1H), 4.21 (q, J = 
7.2 Hz, 2H), 4.06 (dd, J = 8.2, 6.6 Hz, 1H), 3.70 (dd, J = 8.2, 6.9 Hz, 1H), 
3.49 (dd, J = 7.1, 4.0 Hz, 1H), 1.49 (d, J = 5.2 Hz, 3H), 1.36 (s, 3H), 1.32 – 
1.27 (m, 3H); 13C NMR (100 MHz, CDCl 3) δ 168.06, 167.55, 165.79, 161.00, 
160.78, 144.22, 133.03, 132.80, 131.94, 131.84, 124.15, 118.95, 118.69, 
118.25, 118.21, 117.04, 116.98, 109.70, 74.80, 73.76, 71.64, 66.04, 60.74, 
26.31, 25.26, 14.18; The enantiopurity was confirmed by HPLC analysis 
(Chiralpak®  IA column, n-Hexane:EtOH = 7:3, 1.0 ml/min), Rac-3g tR= 7.950 
min, tR = 22.312 min, (S,S)-3g tR= 7.561 min; []D
25 +87.9 (c = 1.0, CHCl3); 
HRMS (ESI) calculated for C26H31O6N2 [M+H]





Preparation of γ,δ-diamino ester derivatives.  
 
Compound (S,S)-7c  
To a clear solution of  3c (91.5 mg, 0.21 mmol) in 
2.1 mL of THF (0.1 M) was added 2.5 equiv of 
concentrated HCl solution (44.1 µL). Stirring the 
reaction mixture at ambient temperature for 4 h 
afforded the corresponding product as a white precipitates. White solid (53.6 
mg, 85 % yield); 1H NMR (400 MHz, DMSO) δ 9.22 (s, 6H), 7.86 – 7.77 (m, 
1H), 6.77 – 6.64 (m, 2H), 6.54 (dd, J = 3.3, 1.9 Hz, 1H), 6.26 (d, J = 15.7 Hz, 
1H), 5.11 (d, J = 5.8 Hz, 1H), 4.72 (dd, J = 7.5, 6.3 Hz, 1H), 4.15 (q, J = 7.1 
Hz, 2H), 1.22 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, DMSO) δ 164.35, 
144.77, 144.75, 137.09, 127.60, 112.35, 111.04, 60.58, 51.80, 48.51, 14.07; 
[]D
25 +28.8 (c = 1.0, MeOH); HRMS (ESI) calculated for C11H17N2O3 
[M+H]+: 225.1239, Found: 225.1228. 
 
Compound (S,S)-7e  
To a clear solution of 3e (88 mg, 0.215 mmol) in 2.1 
mL of THF (0.1 M) was added 2.5 equiv of 
concentrated HCl solution (45 µL). Stirring the 
reaction mixture at ambient temperature for 4 h afforded the corresponding 
product as a white precipitates. White solid (51.5 mg, 87 % yield); 1H NMR 
(400 MHz, DMSO) δ 8.89 (s, 6H), 6.90 (dd, J = 15.8, 7.7 Hz, 1H), 6.36 (d, J 
= 15.8 Hz, 1H), 4.50 – 4.34 (m, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.57 (dd, J = 
6.0, 4.0 Hz, 1H), 2.08 – 1.94 (m, 1H), 1.23 (t, J = 7.1 Hz, 3H), 1.02 (d, J = 6.9 
Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, DMSO) δ 164.53, 









  To a clear solution of 3f (91.5 mg, 0.21 mmol) in 
2.1 mL of THF (0.1 M) was added 2.5 equiv of 
concentrated HCl solution (44.1 µL). Stirring the 
reaction mixture at ambient temperature for 4 h 
afforded the corresponding product as a white precipitates. White solid (85 % 
yield); 1H NMR (400 MHz, DMSO) δ 8.90 (s, 6H), 6.91 (dd, J = 15.8, 7.4 Hz, 
1H), 6.33 (d, J = 15.8 Hz, 1H), 4.48 (t, J = 6.2 Hz, 1H), 4.17 (q, J = 7.1 Hz, 
2H), 3.53 (t, J = 4.6 Hz, 1H), 1.81 – 1.51 (m, 6H), 1.40 – 1.26 (m, 1H), 1.23 (t, 
J = 7.1 Hz, 3H), 1.21 – 0.96 (m, 4H); 13C NMR (100 MHz, DMSO) δ 164.96, 
138.95, 126.71, 60.97, 56.56, 52.24, 36.32, 30.16, 27.07, 26.01, 25.66, 14.50; 
[]D
25 -39.3 (c = 1.0, MeOH); HRMS (ESI) calculated for C13H25N2O2 




















About a decade ago, resonance assisted hydrogen bond directed diaza-Cope 
rearrangement by Chin et al.1 was pioneered for the stereospecific synthesis of 
chiral vicinal diamines, which had been based on the seminal works on diaza-
Cope rearrangement by Vögtle and Goldschmitt.2 Gilli et al. previously 
introduced the concept of resonance assisted hydrogen bonds (RAHBs) to 
demonstrate the synergistic interplay between π-delocalization and H-bonding 
in 2-hydroxyphenyl aldimine.3 Since the RAHB directed DCR based on both 
seminal works was introduced, this method has been used for the preparation 
of a variety of chiral diamines4 including C2-symmetric aryl-
5 and alkyl-6 
substituted diamines as well as non-symmetrical chiral diamines.7 In addition, 
wide ranging applications of this method have been reported including tuning  
 
 
Figure III-1. Applications of Diamines Derived from hpen 
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of reactivity and stereoselectivity of transition metal based catalysts (Ir(III),8 
Ru(II),9 reactivity Rh(II),10 Ni(II),11 Pd(II)12) and organocatalyst13 as well as 
developing chiral auxiliary,14 sensors,15 molecular levers16 and microporous 
materials (Figure III-1).17  
In all of these rearrangement reactions, imine formation between hpen and 
aldehydes is a key reaction for the preparation of the chiral diamines. Chin et 
al. showed that mixed diimines formed between hpen and methyl pyruvate 
and aldehydes undergo diaza-Cope rearrangement to give -substituted syn-
,β-diimino esters.7b However, it has been a challenge to obtain diaza-Cope 
rearrangement of diimines formed exclusively from ketones. While other 
interesting methods have been developed for the synthesis of twinned alanine  
 
 




derivatives,18 stereospecific versions have not been reported (Scheme III-1). 
Here we report the first such example using methyl pyruvate as the ketone 
for stereospecific synthesis of a twinned alanine ester with two quaternary 
chiral centers. DFT computation provides interesting insights into the origin 
of stereospecificity as well as the rate and equilibrium constants for the facile 
rearrangement reaction. 
 
III-2. Result and Discussion 
 
In a typical experiment, (R,R)-hpen (0.50 g) was added to neat methyl 
pyruvate (2.0 mL, approx. 10 equiv) and the mixture was stirred at ambient 
temperature for 14 h (Scheme III-2).  
 
 




The crude product (3) was purified by column chromatography followed by 
crystallization. 1H NMR of the crude product in CDCl3 shows that the 
diastereomeric purity of 3 is over 94%. The enantiopurity of 3 (>99% ee) is 
greater than its diastereopurity as determined by chiral HPLC analysis and 
also as expected from the computational studies shown below. The crystal 
structure of 3 reveals that the two chiral centers are both R in configuration 
(Figure III-3). Thus the diaza-Cope rearrangement with diimines formed from 
methyl pyruvate and hpen takes place stereospecifically as it does with 
diimines formed from aldehydes and hpen. 
 
 
Figure III-2. Crystal Structure of Chiral Diimine 3. 
Time dependent 1H NMR shows that the one pot reaction for formation of 3 
from hpen and methyl pyruvate proceeds by initial formation of the 
imidazolidine intermediate (1) that can be isolated. This five-membered ring 
forms cleanly within 2 h from the reaction of hpen and methyl pyruvate. The 
aminal carbon in the five-membered ring is not a stereogenic center due to the 
pseudo C2 symmetry of 1. Reaction of the imidazolidine ring with a second 
equivalent methyl pyruvate apparently gives the initial diimine (2) that 
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rearranges to give 3.  
It is generally difficult to obtain diaza-Cope rearrangement of diimines 
formed between hpen and ketones as this will result in formation of sterically 
hindered diimines with two quaternary carbons attached to each other. 
Furthermore, controlling stereospecificity for the rearrangement is 
considerably more challenging with diimines formed with ketones than those 
formed with aldehydes. Interestingly, diimines formed from hpen and methyl 
pyruvate undergo diaza-Cope rearrangement smoothly and cleanly at ambient 
temperature with excellent stereospecificity. The diaza-Cope rearrangement of 
the diimine formed between hpen and methyl pyruvate is expected to go 
through a six-membered ring transition state 4a, 4b or 4c (Figure III-3). 
 
Figure III-3. Transition States of 4. (A) Both carboxylate groups in equatorial 
position (4a). (B) One carboxylate group in equatorial position, the other in 
axial position (4b). (C) Both carboxylate groups in axial position (4c). 
 
DFT computation (B3LYP at the 6-31G* level)19 shows that 4a is the most 
stable followed by 4b (ΔΔH‡ = 1.49 kcal/mol) and 4c (ΔΔH‡ = 2.63 kcal/mol). 
The most stable transition state (4a) with both carboxylate groups in 
equatorial positions leads to formation of the product diimine with (R,R) 
configuration (3) as observed experimentally through X-ray crystallography 
(Figure III-1) and chiral HPLC analysis. The second most stable transition 
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state (4b) leads to formation of the meso diimine product. The above 
transition state energy difference (1.49 kcal/mol) translates to formation of 
about 10% of the diimine in the meso form. Consistent with computation, 1H 
NMR of the crude rearrangement product indicates that about 3% of the 
rearranged diimine appears to be in the meso form. The least stable transition 
state (4c) with both carboxylate groups in axial positions leads to formation of 
the diimine product with (S,S) configuration. DFT computation shows that the 
amount of the (S,S)-enantiomer formed from the least stable transition state 
(ΔΔH‡ = 2.63 kcal/mol) would be less than 2%. Consistent with computation, 
we do not observe any of the (S,S)-enantiomer through chiral HPLC analysis. 
X-ray crystallography was used to determine the product configuration.  
The energies of the initial diimines leading to transitions states 4a, 4b and 4c 
are provided in the Appendix C. If the starting E and Z diimines are in rapid 
equilibrium, only the transition state energies determine the product 
distribution according to the Curtin-Hammett principle.20 
We have not been able to synthesize the analogous diimines using hpen and 
acetone or acetophenone in place of methyl pyruvate. DFT computation 
provides some interesting insights into why methyl pyruvate is a particularly 
useful ketone for the rearrangement reaction. Rearrangement of 2 to 3 
(Scheme III-2) is a downhill reaction (ΔH = -6.61 kcal/mol) with a relatively 
low energy barrier (ΔH
‡
 = 12.8 kcal/mol). By comparison, rearrangement of 
the diimine formed between hpen and acetophenone (5a) to form the product 
diimine (6a) is an uphill reaction (ΔH = 5.09 kcal/mol, Scheme III-3). This 
thermodynamic barrier can be lowered with electron withdrawing substituents 
such as chloro (ΔH = 4.56 kcal/mol, 5b), cyano (ΔH = 3.77 kcal/mol, 5c) or 
nitro (ΔH = 3.52 kcal/mol, 5d) groups. However, none of these reactions with 
substituted acetophenones are thermodynamically downhill reactions as the 




Scheme III-3. Comparison of Energy Barrier Following p-Substituents on 
Acetophenones (Energy values in kcal/mol).19 
 
 
Scheme III-4. Comparison of Diimine Formation From hpen with 
Acetone/Methyl Pyruvate (Energy values in kcal/mol).19 
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While rearrangement of diimine formed between hpen and acetone (7) is 
thermodynamically favorable (ΔH = -4.20 kcal/mol, Scheme III-4), it has a 
relatively large energy barrier to form the product diimine (9). The energy 
barrier for formation of 9 is about 8.68 kcal/mol greater than that for the 
rearrangement of the diimine formed with hpen and methyl pyruvate (2). The 
greater energy barrier translates to about 2 x 106-fold decrease in rate at room 
temperature. This slowing down of the rearrangement reaction may be due to 
the unfavorable steric effects of four sp3 hybridized carbon atoms (methyl 
groups) coming together at the transition state.  
Toward a better understanding of the relationship between the experimental 
data and calculation results, further conformational study has been 
investigated. In organic chemistry textbooks, the 1,3-diaxial strain is greater 
for methane than for esters,21 Thus it should be better to have the ester in the 
axial position than the methyl. However, we need to be careful when 
extending this to systems with many substituents.  
DFT computation (B3LYP at the 6-31G* level) shows that 10a is more stable 







Furthermore, computation shows that 11a is more stable than 11b as expected 
from above conformation 10.  
However, when we bring the substituents closer together the trend of energy 
difference is reversed. Here it is better to have the carboxylates together in the 
equatorial positions as in 12b than to have the methyl groups together in the 




Further analysis below shows that it is energetically better to have 
carboxylates together than to have methyl groups together on equatorial 
positions in 1,2-disubstituted cyclohexanes. Computation predicts that 1,2-
dimethyl cyclohexane (13b) is less stable than 1,4-dimethyl cyclohexane (13a) 
due apparently to greater steric effect (gauche interaction) when the two 




The gap is reduced significantly for the dicarboxylates. Indeed, the 1,2-
disubstituted carboxylate (14b) is more stable than the 1,4-disubstituted one 
(14a). Thus there appears to be even energetically favorable interactions 





The energy gap becomes much bigger in case of the t-butyl substituent 






A diamino diacid with two quarternary chiral centers has been synthesized 
with excellent stereospecificity under mild conditions by diaza-Cope 
rearrangement. This represents the first time a ketone has been used 
exclusively for the rearrangement reaction. DFT computation shows that the 
rearrangement is thermodynamically more favorable with electron deficient 
ketones like methyl pyruvate over acetophenones. Furthermore, the 
rearrangement is kinetically more favorable with conjugated ketones like 
methyl pyruvate over alkyl ketones due to greater steric crowding at the 
transition state in the latter case. Additionally, conformational study shows 
that it is more favourable to have both carboxylates together than to have both 
methyl groups on the equatorial position, resulting in the choice of transition 







Commercially available compounds were used without further purification or drying. 
The 1H NMR and 13C NMR spectra were recorded on a Varian Mercury 400 
spectrometer or a Bruker Advance III 400 MHz spectrometer. High resolution mass 
spectra (HRMS) were obtained on an ABI/Sciex QStar Mass Spectrometer (ESI) at 
Advanced Instrumentation for Molecular Structure (AIMS) at the University of 
Toronto and on a ThermoFinnigan LCQ™ Classic, Quadrupole Ion-Trap Mass 
Spectrometer at Seoul National University. HPLC analysis was performed on a 
Hewlett-Packard 1100 Series HPLC, UV detection monitored at 254.4 nm using a 
Chiralpak®  IA column (25cm). Optical rotation was obtained at 589 nm using a 
Rudolph Autopol IV polarimeter at the University of Toronto and on a JASCO P-1030 
automatic polarimeter at Seoul National University. Melting points were recorded 
using an Electrothermal IA 9100 digital melting point apparatus. Reactions were 
monitored using 1H NMR spectroscopy. Chromatography was performed on Silicycle 
230-400 mesh silica gel and thin-layer chromatography (TLC) was performed on 
EMD Silica Gel 60 F254 plates. Visualization of the developed plates was performed 
under UV light (254 nm). All calculations were performed using Spartan ‘08 for 
Windows from Wavefunction Inc. 
 
Preparation of 5-membered imidazolidine intermediate (1) 
 
After adding methyl pyruvate (407 µL, 4.51 mmol) to (R,R)-1,2-bis(2-
hydroxylphenyl)-1,2-diaminoethane (1.0 g, 4.1 mmol) in CHCl3, the reaction mixture 
was stirred at 50 oC for 1 h until starting material was all removed. The solvent was 
removed in vacuo and 2 mL of diethyl ether was added to afford a desired product and 
5 mL of n-hexane was added to reduce the loss of isolated yield. The solid was 
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filtered, washed with 10 mL of n-hexane, and dried in vacuum. The desired product 
was obtained as light yellow solid (1.25 g, 93% yield). 
 
Compound (R,R)-1 
Light yellow solid (93% yield), mp 137-138 oC  
1H NMR (400 MHz, CDCl3): δ 10.74 (s, 2H), 7.23 – 7.08 (m, 
2H), 6.92 – 6.80 (m, 2H), 6.61 (td, J = 7.4, 1.1 Hz, 1H), 6.56 (td, 
J = 7.5, 1.1 Hz, 1H), 6.33 (dd, J = 7.6, 1.6 Hz, 1H), 6.20 (dd, J = 
7.6, 1.5 Hz, 1H), 4.64 (d, J = 9.7 Hz, 1H), 4.36 (d, J = 9.8 Hz, 1H), 3.91 (s, 3H), 1.79 
(s, 3H). 13C NMR (101 MHz, CDCl3): δ 174.4, 157.5, 157.3, 130.0, 129.7, 129.5, 
129.3, 119.5, 119.4, 119.1, 118.9, 117.2, 117.0, 76.4, 67.4, 66.1, 53.6, 27.3. []D
24 









After adding methyl pyruvate (2.05 mL, 1.0 M) with activated molecular sieve (3 Å ) 
to (R,R)-1,2-bis(2-hydroxylphenyl)-1,2-diaminoethane (0.50 g, 2.05 mmol) in CHCl3, 
the mixture was stirred at room temperature for 14 h until 5-membered ring was all 
removed. Salicylaldehyde (218 µL, 2.05 mmol) was added to the reaction mixture and 
the mixture was stirred at room temperature for 1 h. The reaction mixture was purified 
using short column chromatography eluting with hexane / ethyl acetate (20 %) to 
remove excess methyl pyruvate and salicylaldehyde. Recrystallization of obtained 
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crude product in diethyl ether / n-hexane gave the desired product as a yellow 
monoclinic crystal (60% yield).  
 
Compound (R,R)-3 
Yellow monoclinic crystal (60% yield), mp 115-116 oC 
1H NMR (400 MHz, CDCl3): δ ppm 12.98 (s, 1H); 8.39 (s, 1H; 
7.34 (t, J = 7.8 Hz, 1H); 7.28 (d, J = 7.6 Hz, 1H); 6.98 (d, J = 
8.4 Hz, 1H); 6.89 (t, J = 7.5 Hz, 1H); 3.76 (s, 3H); 1.70 (s, 3H). 
13C NMR (100 MHz, CDCl3): δ ppm 172.0, 165.2, 161.1, 133.2, 132.4, 119.0, 118.9, 
117.5, 73.6, 53.0, 19.3. The enantiopurity was confirmed by HPLC analysis 
(Chiralpak®  IA column, n-Hexane:i-PrOH = 90:10, 1.0 ml/min); Rac-3 tR= 8.96 min, 
tR = 16.34 min, (R,R)-3 tR= 16.32 min, (S,S)-3 tR= 8.98 min. []D
27 +175.95 (c = 1.0, 
CHCl3). HRMS (ESI) calculated for C22H25N2O6 [M+H]











Sugar as Chiral Derivatizing Agent for 
the Determination of the Enantiopurity 








We have demonstrated the importance and usefulness of chiral vicinal 
diamines in previous Chapters. As a result, there has been much interest in 
developing stereoselective methods for the preparation of C2-symmetric 
diamines1 as well as in developing convenient methods for determining their 
enantiopurity.2 NMR spectroscopic analysis has emerged as a quite useful tool 
for the determination of enantiopurities and absolute configurations of various 
chiral compounds. Many NMR analysis methods have been recently 
developed3 as interesting chiral derivatizing agents (CDAs) and chiral shift 
reagents (CSAs) for determining the enantiopurities of carboxylic acids,4 
alcohols,5 cyanohydrin6 and amines.7 In general, CSAs are more convenient to 
use since prior derivatization is not required as with most CDAs. Elegant 
macrocyclic CSAs that rely on hydrogen bonding have been developed.8 
However, they are more difficult to synthesize than typical CDAs. An 
innovative alternative is to have easy to make CDAs that rely on reversible 
covalent bonds such as imines.9 Thus chiral aldehydes are potentially valuable 
as CDAs for determining the enantiopurity of primary amines.10 To the best of 
our knowledge, we found one literature example for using aldehydes for 
determining the enantiopurity of a protection-free C2-symmetric vicinal 
diamine.11 In that interesting study, binol and 2-formylphenylboronic acid12 
was used as CDA to determine the enantiopurity of diphenylethylenediamine 
(dpen). Sugars are some of the cheapest and most readily available chiral 
aldehydes known and have been popular as chiral building blocks for 
developing drugs and catalysts.13 Here we report the use of ribose and 
arabinose as CDAs for the determination of the enantiopurity of C2-symmetric 
chiral diamines including dpen.
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IV-2. Result and Discussion 
 
Diamines react with aldehyde in ribose or arabinose to form imidazolidines. 
There are three 1H NMR signals (HA, HB and HC) in the imidazolidines that 
may be used for determining the enantiopurity of diamines (Scheme IV-1). In 
a typical experiment, vicinal diamine (0.035 mmol) was added to 1.3 equiv of 
D-ribose or D-arabinose in methanol-d4 (0.7 ml) and stirred for 5 h at 50 
oC to 
afford the corresponding imidazolidine. Excess sugar was used to drive the 
reaction to completion and prevent kinetic effects. 1H NMR shows that 
diimine formation or diaza-Cope rearrangement1i do not take place under our 
experimental conditions.  
In order to study the scope of our protocol, a series of C2-symmetric 
diamines were tested. The resulting 1H NMR spectrum and the difference in 
chemical shifts (δ) of the diastereomers for each of the diamines are 
summarized in Table IV-1. 
 
Scheme IV-1. Imidazolidines from Diamines and Sugars. 
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a Reagents and condition: diamines (0.035 mmol), methanol-d4 (0.7 mL, 0.05 M), 
sugar (0.046 mmol), 50 oC, 5 h.  
b Chemical shift difference.  



































In cases of diamines 1, 3, 4, 5 and 6, the HB doublet signal from the 
imidazolidine formed with D-ribose was used to determine the enantiopurity 
of the diamines. In each of these imidazolidines, the HB signals obtained with 
the (R,R)-diamines appeared upfield of those obtained with the (S,S)-diamines. 
For diamine 2, best resolution was obtained with the HC signal of the 
imidazolidine formed with D-arabinose. In case of 7, the HA signal of the 
imidazolidine formed with D-ribose was used to determine the enantiopurity. 
The two HA signals in the imidazolidine ring are different and appear as an  
 
Figure IV-1. Expansion of the Aminal Proton Region of 1H NMR 
Enantiomerically Mixed dpen and D-(-)-ribose. 
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AB signal. Our method did not work for determining the enantiopurity of 1,2-
diaminocyclohexane (dach). D-ribose or D-arabinose does not cleanly form 
imidazolidine ring with dach due to ring strain.11 
We tested the reliability of our sugar-based CDA-NMR protocol using 
samples of 1 with known enantiopurities (0, 32, 81, 94 and >99% ee RR-1).  
There is excellent agreement between the enantiopurities determined using 
our protocol and the known enantiopurities of 1 as shown in Figure IV-1. We 
also determined the enantiopurities of 1 using chiral HPLC analysis. For the 
preparation of each samples, we used the diaza-Cope rearrangement to 
synthesize product diimines, followed by hydrolysis of the product diimines 
and subsequent neutralization. The enantiopurity of each sample was 
confirmed by chiral HPLC analysis at the diimine stage (Chiralpak®  IA 
column, n-hexane:iso-propyl alcohol = 9:1, 1.0 ml/min). There is also an 
excellent agreement between our sugar-based CDA-NMR and the chiral 
HPLC methods for determining the enantiopurities of 1 (Figure IV-2). 
 




Our sugar-based protocol for determining the enantiopurity of vicinal 
diamines provides error limits well within the accepted 2% range for 1H NMR 
(Table IV-2).14  
 
Table IV-2. Comparison of NMR Spectra and HPLC Analysis. 
 










We have shown that readily available sugar molecules can be used as chiral 
derivatizing agents for determining the enantiopurity of a range of vicinal 
diamines. This 1H NMR method is simple and convenient and does not 
require any prior derivatization of the sugar or the diamine. The accuracy of 









All materials were obtained from commercial supplier and used without 
further purification. The 1H NMR, 13C NMR and 19F NMR spectra were 
recorded on an Agilent DD2MR400 400 MHz spectrometer in Seoul National 
University (SNU) and the NMR solvent (methanol-d4) was from Cambridge 
Isotope Laboratories, Inc. High resolution mass spectra (HRMS) were 
obtained on a ThermoFinnigan LCQ™ Classic, Quadrupole Ion-Trap Mass 
Spectrometer. Chiral HPLC analysis was performed on a Hewlett-Packard 
1100 Series HPLC, UV detection monitored at 254.4 nm using a Chiralpak
®
 
IA column (25cm). 
 
Preparation of chiral diamines 
 
All diamines were prepared through diaza-Cope rearrangement (DCR) with 
(R,R)/(S,S)-1,2-bis(2-hydroxyphenyl)-1,2-diaminoethane (hpen) following 
Chin’s previous paper (J. Am. Chem. Soc. 2008, 130, 12184). And the 
neutralization of chiral diamine dihydrochloride was performed with 10N 









1H NMR (400 MHz, CD3OD) δ 7.23 – 7.05 (m, 10H), 3.96 (s, 
2H). 13C NMR (101 MHz, CD3OD) δ 143.80, 129.12, 128.38, 
128.05, 63.86. HRMS (ESI) calculated for C14H17N2 [M+H]
+ : 




1H NMR (400 MHz, CD3OD) δ 6.99 (td, J = 8.0, 1.7 Hz, 2H), 
6.81 (dd, J = 7.5, 1.6 Hz, 2H), 6.71 (dd, J = 8.1, 1.0 Hz, 2H), 
6.57 (td, J = 7.4, 1.1 Hz, 2H), 4.30 (s, 2H). 13C NMR (101 MHz, 
CD3OD) δ 157.53, 130.19, 129.23, 129.11, 119.87, 117.42, 
60.60. HRMS (ESI) calculated for C14H17N2 [M+H]





1H NMR (400 MHz, CD3OD) δ 7.02 (d, J = 8.7 Hz, 4H), 
6.74 (d, J = 8.7 Hz, 4H), 3.88 (s, 2H), 3.71 (s, 6H). 13C 
NMR (101 MHz, CD3OD) δ 160.09, 135.84, 129.41, 
114.44, 63.26, 55.55. HRMS (ESI) calculated for C14H17N2 








Compound 4  
(R,R)/(S,S)-1,2-bis(4-fluorophenyl)-1,2-diaminoethane 
1H NMR (400 MHz, CD3OD) δ 7.11 (dd, J = 8.7, 5.4 Hz, 
4H), 6.90 (t, J = 8.8 Hz, 4H), 3.92 (s, 2H). 13C NMR (101 
MHz, CD3OD) δ 164.44, 162.01, 139.87, 139.84, 130.21, 
130.13, 115.83, 115.61, 63.42. 19F NMR (376 MHz, CD3OD) 
δ -117.82. HRMS (ESI) calculated for C14H17N2 [M+H]





1H NMR (400 MHz, CD3OD) δ 7.11 (dd, J = 8.7, 5.4 Hz, 
4H), 6.90 (t, J = 8.8 Hz, 4H), 3.92 (s, 2H). 13C NMR (101 
MHz, CD3OD) δ 146.92, 129.05, 128.73, 127.68, 125.52, 
124.65, 124.61, 124.57, 124.54, 122.82, 62.15. 19F NMR 
(376 MHz, cd3od) δ -64.05. HRMS (ESI) calculated for C14H17N2 [M+H]
+ : 





H NMR (400 MHz, CD3OD) δ 7.50 (dd, J = 7.8, 1.2 Hz, 2H), 
7.14 (td, J = 7.5, 0.9 Hz, 2H), 7.02 (td, J = 7.5, 1.4 Hz, 2H), 
6.93 – 6.83 (m, 2H), 4.27 (s, 2H), 1.94 (s, 6H). 13C NMR (101 
MHz, CD3OD) δ 142.31, 136.74, 131.11, 127.92, 127.50, 
126.97, 58.22, 19.62. HRMS (ESI) calculated for C14H17N2 [M+H]
+ : 







1H NMR (400 MHz, CD3OD) δ 8.14 (d, J = 8.5 Hz, 2H), 7.67 
(dd, J = 16.2, 7.4 Hz, 4H), 7.59 (d, J = 8.2 Hz, 2H), 7.47 – 7.27 
(m, 6H), 5.10 (s, 2H). 13C NMR (101 MHz, CD3OD) δ 138.83, 
133.74, 130.84, 128.29, 127.15, 125.34, 124.84, 124.73, 123.75, 
122.52, 55.60. HRMS (ESI) calculated for C14H17N2 [M+H]
+ : 
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1H NMR spectrum of 3b (400 MHz, CDCl3) 
 
 




1H NMR spectrum of 3c (400 MHz, CDCl3) 
 
 




1H NMR spectrum of 3d (400 MHz, CDCl3) 
 
 




1H NMR spectrum of 3e (400 MHz, CDCl3) 
 
 




1H NMR spectrum of 3f (400 MHz, CDCl3) 
 
 




1H NMR spectrum of 3g (400 MHz, CDCl3) 
 
 









13C NMR spectrum of 7c (100 MHz, DMSO-d6) 
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1H NMR spectrum of 7f (400 MHz, DMSO-d6) 
 
 
13C NMR spectrum of 7f (100 MHz, DMSO-d6) 
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Chapter 3.  
1H NMR spectrum of 1 (400 MHz, CDCl3) 
 
 
13C NMR spectrum of 1 (101 MHz, CDCl3) 
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1H NMR spectrum of 3 (400 MHz, CDCl3) 
 
 





1H NMR spectrum of 1 (400 MHz, MeOD-d3) 
 
 




1H NMR spectrum of 2 (400 MHz, MeOD-d3) 
 
13C NMR spectrum of 2 (101 MHz, MeOD-d3) 
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1H NMR spectrum of 3 (400 MHz, MeOD-d3) 
 
 




1H NMR spectrum of 4 (400 MHz, MeOD-d3) 
 
 




19F NMR spectrum of 4 (376 MHz, MeOD-d3) 
 
 




13C NMR spectrum of 5 (101 MHz, MeOD-d3) 
 
 




1H NMR spectrum of 6 (400 MHz, MeOD-d3) 
 
 




1H NMR spectrum of 7 (400 MHz, MeOD-d3) 
 
 



























Chiralpak®  IA column, 100% Ethyl alcohol + diethyl amine (DEA) 0.1%, 0.3 
ml/min 
 





























































































































































































































Chiralpak®  IA column, n-hexane:iso-propyl alcohol = 9:1, 1.0 ml/min 
 













































Energy      
(hartree) 









4x -1341.372087 0.454791925 -1340.894890  
4y -1418.777069 0.488232908 -1418.264757  
4z -1454.911729 0.478609941 -1454.408260  
4w -1341.798241 0.481893163 -1341.291604  
5x -1341.343196 0.450728623 -1340.869500 i 203.636 
5y -1418.749933 0.484338221 -1418.240980 i 205.911 
5z -1454.886743 0.475212531 -1454.386236 i 247.939 
5w -1341.767938 0.478923557 -1341.263867 i 228.404 
6x -1341.382937 0.454273700 -1340.906352  
6y -1418.785293 0.487841592 -1418.273480  
6z -1454.924200 0.478264978 -1454.421228  
6w -1341.812763 0.482813597 -1341.305525  





Transition state of compound 4 ( Figure III-2) 
 
Enthalpy values in kcal/mol. 
 
Molecules 
Energy      
(hartree) 








2a -1413.627618  -1413.194171 -1413.164382  
2b -1413.624778 -1413.190705 -1413.160212  
2c -1413.621111 -1413.187197 -1413.157592  
3a, 3c -1413.638968 -1413.204239 -1413.174917  
3b -1413.636684 -1413.203042 -1413.173175  
4a -1413.605623 -1413.173733 -1413.144003 i 265.644 
4b -1413.603385 -1413.171061 -1413.141625 i 277.903 
4c -1413.601180 -1413.169660 -1413.139813 i 277.864 
B3LYP/6-31G (d) level 
171 
 
The effect of para-substituents on acetophenone (Scheme III-2) 
 
Enthalpy values in kcal/mol. 
Molecules 
Energy      
(hartree) 









5a -1419.999729 -1419.488580 -1419.458128 
16.1 
TS-a -1419.969228 -1419.461794 -1419.432493 
5.09 
6a -1419.990193 -1419.479841 -1419.450020 
Cl 
5b -2339.191082 -2338.699175 -2338.666259 
16.0 
TS-b -2339.161835 -2338.673315 -2338.640794 
4.56 
6b -2339.182350 -2338.69132 -2338.658987 
CN 
5c -1604.483396 -1603.975129 -1603.940979 
14.2 
TS-c -1604.457011 -1603.951937 -1603.918286 
3.77 
6c -1604.475962 -1603.968511 -1603.934976 
NO2 
5d -1828.999027 -1828.482670 -1828.447075 
13.8 
TS-d -1828.973518 -1828.460264 -1828.425153 
3.52 
6d -1828.992002 -1828.476485 -1828.441466 




In Scheme III-3, 
 
 
In conformational study 
 
Molecules 
Energy      
(hartree) 






10a -503.066374 -502.8236778 0.253863912 -502.8125101 
10b -503.064069 -502.8214556 0.253811388 -502.8102576 
11a -770.252422 -769.9392989 0.329012264 -769.9234097 
11b -770.247185 -769.9336726 0.329321805 -769.9178632 
12a -770.237393 -769.9235433 0.329627995 -769.907765 
12b -770.239837 -769.9255815 0.329977185 -769.9098598 
13a -314.510961 -314.2835823 0.236500286 -314.2744607 
13b -314.50861 -314.2818954 0.235789335 -314.2728207 
14a -691.627030 -691.3697703 0.270526604 -691.3565034 
14b -691.628181 -691.3707393 0.270710836 -691.3574702 
15a -550.378500 -549.9819231 0.412528699 -549.9659713 
15b -550.346154 -549.9468732 0.414749114 -549.9314049 
B3LYP/6-31G (d) level 
Molecules 
Energy      
(hartree) 









2 -1413.627618  -1413.194171 -1413.164382  
3 -1413.638968 -1413.204239 -1413.174917  
4a -1413.605623 -1413.173733 -1413.144003 i 265.644 
7 -1036.526725 -1036.122058 -1036.097803  
8 -1036.488949  -1036.087035 -1036.063595 i 254.482 
9 -1036.532881  -1036.127726 -1036.104496  
















In Chapter II,  
 
Crystal structure of diimine 3d 
 
Table S-II-1. Crystal data and structure refinement for d1309. 
 
Identification code  d1309  
Empirical formula  C27 H24 Cl2 N2 O4 
Formula weight  511.38  
Temperature  147(2) K  
Wavelength  1.54178 Å   
Crystal system  Orthorhombic 
Space group  P 21 21 21  
Unit cell dimensions a = 10.5373(8) Å  a= 90°. 
 b = 11.2169(8) Å  b= 90°. 
 c = 43.787(3) Å  g = 90°. 
Volume 5175.5(7) Å 3  
Z 8  
Density (calculated) 1.313 Mg/m3  
Absorption coefficient 2.548 mm-1  
F(000) 2128  
175 
 
Crystal size 0.22 x 0.18 x 0.08 mm3 
Theta range for data collection 2.02 to 66.69°. 
Index ranges -12<=h<=12, -8<=k<=13, -50<=l<=52 
Reflections collected 33179  
Independent reflections 8861 [R(int) = 0.0333] 
Completeness to theta = 66.69° 97.9 %   
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.6640 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8861 / 5 / 662 
Goodness-of-fit on F2 1.044  
Final R indices [I>2sigma(I)] R1 = 0.0298, wR2 = 0.0753 
R indices (all data) R1 = 0.0308, wR2 = 0.0760 
Absolute structure parameter 0.014(8)  
Largest diff. peak and hole 0.352 and -0.346 e.Å -3 
 
Table S-II-2.  Atomic coordinates  ( x 104) and equivalent  isotropic 
displacement parameters (Å 2x 103) 




x y z U(eq) 
Cl(1A) 13312(1) 13857(1) 5103(1) 41(1) 
Cl(2A) 10963(1) 13921(1) 6215(1) 67(1) 
O(1A) 15454(1) 11643(1) 5409(1) 48(1) 
O(2A) 9760(1) 9143(1) 5744(1) 47(1) 
O(3A) 7667(2) 14464(1) 5392(1) 56(1) 
N(1A) 13139(1) 11966(1) 5618(1) 31(1) 
N(2A) 10687(1) 10948(1) 5440(1) 29(1) 
C(1A) 11927(2) 12592(2) 5647(1) 30(1) 
C(2A) 11005(2) 12200(2) 5389(1) 29(1) 
C(3A) 13282(2) 11009(2) 5774(1) 32(1) 
C(4A) 14446(2) 10325(2) 5768(1) 32(1) 
C(5A) 15505(2) 10683(2) 5596(1) 36(1) 
C(6A) 16628(2) 10045(2) 5618(1) 44(1) 
176 
 
C(7A) 16691(2) 9042(2) 5801(1) 46(1) 
C(8A) 15651(2) 8654(2) 5963(1) 43(1) 
C(9A) 14536(2) 9300(2) 5948(1) 38(1) 
C(10A) 10980(2) 10216(2) 5229(1) 32(1) 
C(11A) 10636(2) 8958(2) 5241(1) 36(1) 
C(12A) 9992(2) 8477(2) 5492(1) 40(1) 
C(13A) 9577(2) 7304(2) 5480(1) 58(1) 
C(14A) 9793(3) 6622(2) 5226(1) 71(1) 
C(15A) 10461(3) 7068(2) 4980(1) 67(1) 
C(16A) 10878(2) 8233(2) 4988(1) 52(1) 
C(17A) 12154(2) 13925(2) 5661(1) 32(1) 
C(18A) 12779(2) 14571(2) 5432(1) 37(1) 
C(19A) 13007(2) 15779(2) 5453(1) 52(1) 
C(20A) 12620(2) 16388(2) 5712(1) 66(1) 
C(21A) 11997(2) 15807(2) 5940(1) 60(1) 
C(22A) 11768(2) 14601(2) 5913(1) 45(1) 
C(23A) 9838(2) 12967(2) 5401(1) 32(1) 
C(24A) 8874(2) 12840(2) 5587(1) 36(1) 
C(25A) 7804(2) 13693(2) 5580(1) 42(1) 
O(4A) 7010(2) 13520(2) 5810(1) 72(1) 
C(26A) 6005(4) 14483(5) 5807(1) 56(1) 
C(27A) 5297(4) 14308(6) 6093(1) 84(2) 
C(26C) 5666(4) 13922(6) 5835(2) 42(2) 
C(27C) 5808(7) 15015(6) 6022(2) 55(2) 
Cl(1B) 2901(1) 7094(1) 2421(1) 48(1) 
Cl(2B) 3251(1) 8325(1) 3625(1) 66(1) 
O(1B) 2514(2) 4078(1) 2687(1) 47(1) 
O(2B) -1966(1) 7328(1) 3545(1) 39(1) 
O(3B) 318(1) 11453(1) 2770(1) 46(1) 
O(4B) -833(2) 11516(1) 3198(1) 50(1) 
N(1B) 1982(1) 5880(1) 3038(1) 31(1) 
N(2B) -482(1) 7195(1) 3081(1) 31(1) 
C(1B) 1808(2) 7162(2) 3091(1) 31(1) 
C(2B) 632(2) 7605(2) 2912(1) 33(1) 
C(3B) 2096(2) 5197(2) 3270(1) 33(1) 
C(4B) 2417(2) 3943(2) 3236(1) 36(1) 
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C(5B) 2637(2) 3440(2) 2949(1) 40(1) 
C(6B) 3010(2) 2257(2) 2925(1) 54(1) 
C(7B) 3158(2) 1586(2) 3188(1) 66(1) 
C(8B) 2931(2) 2056(2) 3471(1) 61(1) 
C(9B) 2562(2) 3232(2) 3495(1) 48(1) 
C(10B) -1274(2) 6500(2) 2952(1) 36(1) 
C(11B) -2406(2) 6102(2) 3110(1) 38(1) 
C(12B) -2703(2) 6520(2) 3404(1) 31(1) 
C(13B) -3774(2) 6102(2) 3555(1) 43(1) 
C(14B) -4546(2) 5285(3) 3417(1) 69(1) 
C(15B) -4287(3) 4886(4) 3125(1) 96(1) 
C(16B) -3234(2) 5290(3) 2973(1) 70(1) 
C(17B) 3072(2) 7765(2) 3020(1) 33(1) 
C(18B) 3638(2) 7769(2) 2733(1) 37(1) 
C(19B) 4810(2) 8279(2) 2675(1) 44(1) 
C(20B) 5478(2) 8781(2) 2909(1) 52(1) 
C(21B) 4989(2) 8783(2) 3200(1) 51(1) 
C(22B) 3798(2) 8280(2) 3252(1) 40(1) 
C(23B) 593(2) 8940(2) 2885(1) 34(1) 
C(24B) -197(2) 9652(2) 3026(1) 40(1) 
C(25B) -186(2) 10956(2) 2978(1) 35(1) 
C(26B) -831(2) 12799(2) 3192(1) 45(1) 
C(27B) -1065(6) 13295(4) 3498(1) 60(2) 
C(27D) -1820(7) 13164(6) 3421(2) 54(2) 
 
Table S-II-3.   Bond lengths [Å ] and angles [°] for  d1309. 
 
Cl(1A)-C(18A)  1.741(2) 
Cl(2A)-C(22A)  1.747(2) 
O(1A)-C(5A)  1.355(2) 
O(1A)-H(1OA)  0.92(3) 
O(2A)-C(12A)  1.355(3) 
O(2A)-H(2OA)  0.92(3) 
O(3A)-C(25A)  1.203(3) 
N(1A)-C(3A)  1.280(2) 
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N(1A)-C(1A)  1.463(2) 
N(2A)-C(10A)  1.276(2) 
N(2A)-C(2A)  1.461(2) 
C(1A)-C(17A)  1.515(3) 
C(1A)-C(2A)  1.554(2) 
C(1A)-H(1AA)  1 
C(2A)-C(23A)  1.501(2) 
C(2A)-H(2AA)  1 
C(3A)-C(4A)  1.447(3) 
C(3A)-H(3AA)  0.95 
C(4A)-C(9A)  1.395(3) 
C(4A)-C(5A)  1.407(3) 
C(5A)-C(6A)  1.386(3) 
C(6A)-C(7A)  1.382(3) 
C(6A)-H(6AA)  0.95 
C(7A)-C(8A)  1.376(3) 
C(7A)-H(7AA)  0.95 
C(8A)-C(9A)  1.383(3) 
C(8A)-H(8AA)  0.95 
C(9A)-H(9AA)  0.95 
C(10A)-C(11A)  1.457(3) 
C(10A)-H(10A)  0.95 
C(11A)-C(16A)  1.398(3) 
C(11A)-C(12A)  1.400(3) 
C(12A)-C(13A)  1.388(3) 
C(13A)-C(14A)  1.367(4) 
C(13A)-H(13A)  0.95 
C(14A)-C(15A)  1.383(4) 
C(14A)-H(14A)  0.95 
C(15A)-C(16A)  1.379(3) 
C(15A)-H(15A)  0.95 
C(16A)-H(16A)  0.95 
C(17A)-C(22A)  1.400(3) 
C(17A)-C(18A)  1.401(3) 
C(18A)-C(19A)  1.379(3) 
C(19A)-C(20A)  1.387(4) 
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C(19A)-H(19A)  0.95 
C(20A)-C(21A)  1.361(4) 
C(20A)-H(20A)  0.95 
C(21A)-C(22A)  1.380(3) 
C(21A)-H(21A)  0.95 
C(23A)-C(24A)  1.311(3) 
C(23A)-H(23A)  0.95 
C(24A)-C(25A)  1.479(3) 
C(24A)-H(24A)  0.95 
C(25A)-O(4A)  1.324(3) 
O(4A)-C(26A)  1.513(3) 
C(26A)-C(27A)  1.472(5) 
C(26A)-H(26A)  0.99 
C(26A)-H(26B)  0.99 
C(27A)-H(27A)  0.98 
C(27A)-H(27B)  0.98 
C(27A)-H(27C)  0.98 
C(26C)-C(27C)  1.482(5) 
C(26C)-H(26C)  0.99 
C(26C)-H(26D)  0.99 
C(27C)-H(27D)  0.98 
C(27C)-H(27E)  0.98 
C(27C)-H(27F)  0.98 
Cl(1B)-C(18B)  1.742(2) 
Cl(2B)-C(22B)  1.734(2) 
O(1B)-C(5B)  1.357(2) 
O(1B)-H(1OB)  0.88(3) 
O(2B)-C(12B)  1.344(2) 
O(2B)-H(2OB)  0.87(3) 
O(3B)-C(25B)  1.195(2) 
O(4B)-C(25B)  1.335(2) 
O(4B)-C(26B)  1.440(2) 
N(1B)-C(3B)  1.277(2) 
N(1B)-C(1B)  1.468(2) 
N(2B)-C(10B)  1.274(2) 
N(2B)-C(2B)  1.460(2) 
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C(1B)-C(17B)  1.525(3) 
C(1B)-C(2B)  1.548(2) 
C(1B)-H(1BA)  1 
C(2B)-C(23B)  1.503(3) 
C(2B)-H(2BA)  1 
C(3B)-C(4B)  1.454(3) 
C(3B)-H(3BA)  0.95 
C(4B)-C(9B)  1.396(3) 
C(4B)-C(5B)  1.398(3) 
C(5B)-C(6B)  1.388(3) 
C(6B)-C(7B)  1.384(4) 
C(6B)-H(6BA)  0.95 
C(7B)-C(8B)  1.369(4) 
C(7B)-H(7BA)  0.95 
C(8B)-C(9B)  1.379(4) 
C(8B)-H(8BA)  0.95 
C(9B)-H(9BA)  0.95 
C(10B)-C(11B)  1.449(3) 
C(10B)-H(10B)  0.95 
C(11B)-C(16B)  1.396(3) 
C(11B)-C(12B)  1.405(2) 
C(12B)-C(13B)  1.391(3) 
C(13B)-C(14B)  1.367(3) 
C(13B)-H(13B)  0.95 
C(14B)-C(15B)  1.382(4) 
C(14B)-H(14B)  0.95 
C(15B)-C(16B)  1.372(4) 
C(15B)-H(15B)  0.95 
C(16B)-H(16B)  0.95 
C(17B)-C(18B)  1.392(3) 
C(17B)-C(22B)  1.395(3) 
C(18B)-C(19B)  1.384(3) 
C(19B)-C(20B)  1.363(3) 
C(19B)-H(19B)  0.95 
C(20B)-C(21B)  1.373(3) 
C(20B)-H(20B)  0.95 
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C(21B)-C(22B)  1.394(3) 
C(21B)-H(21B)  0.95 
C(23B)-C(24B)  1.308(3) 
C(23B)-H(23B)  0.95 
C(24B)-C(25B)  1.478(3) 
C(24B)-H(24B)  0.95 
C(26B)-C(27B)  1.472(4) 
C(26B)-H(26E)  0.99 
C(26B)-H(26F)  0.99 
C(27B)-H(27G)  0.98 
C(27B)-H(27H)  0.98 
C(27B)-H(27I)  0.98 
C(27D)-H(27J)  0.98 
C(27D)-H(27K)  0.98 

































































































































































































































Table S-II-4.   Anisotropic displacement parameters  (Å 2x 103) for d1309.  
The anisotropic displacement factor exponent takes the form:  -2p2[ h2 
a*2U11 + ...  + 2 h k a* b* U12 ] 
 
 
U11 U22  U33 U23 U13 U12 
Cl(1A) 40(1)  40(1) 41(1)  2(1) 7(1)  -3(1) 
Cl(2A) 69(1)  83(1) 48(1)  -31(1) 19(1)  -6(1) 
O(1A) 37(1)  50(1) 56(1)  18(1) 13(1)  10(1) 
O(2A) 43(1)  48(1) 49(1)  10(1) 6(1)  0(1) 
O(3A) 43(1)  52(1) 73(1)  6(1) -12(1)  15(1) 
N(1A) 26(1)  38(1) 29(1)  -4(1) -1(1)  4(1) 
N(2A) 25(1)  31(1) 31(1)  -2(1) -3(1)  1(1) 
C(1A) 25(1)  37(1) 30(1)  -4(1) 1(1)  3(1) 
C(2A) 27(1)  30(1) 29(1)  -4(1) 0(1)  -2(1) 
C(3A) 27(1)  41(1) 27(1)  -2(1) -1(1)  -1(1) 
C(4A) 27(1)  39(1) 29(1)  -1(1) -3(1)  1(1) 
C(5A) 33(1)  39(1) 36(1)  3(1) 1(1)  2(1) 
C(6A) 31(1)  49(1) 53(1)  6(1) 7(1)  7(1) 
C(7A) 35(1)  47(1) 55(1)  3(1) -5(1)  12(1) 
C(8A) 42(1)  42(1) 44(1)  8(1) -7(1)  4(1) 
C(9A) 33(1)  44(1) 36(1)  4(1) -3(1)  -3(1) 
C(10A) 28(1)  34(1) 36(1)  0(1) 0(1)  3(1) 
C(11A) 30(1)  29(1) 49(1)  0(1) -1(1)  6(1) 
C(12A) 26(1)  35(1) 58(1)  5(1) 0(1)  8(1) 
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C(13A) 42(1)  32(1) 99(2)  13(1) 12(1)  4(1) 
C(14A) 60(2)  26(1) 126(2)  -4(1) 7(2)  3(1) 
C(15A) 69(2)  37(1) 95(2)  -18(1) 9(1)  7(1) 
C(16A) 56(1)  33(1) 66(1)  -10(1) 9(1)  8(1) 
C(17A) 21(1)  36(1) 39(1)  -13(1) -6(1)  2(1) 
C(18A) 24(1)  36(1) 51(1)  -9(1) -5(1)  2(1) 
C(19A) 34(1)  38(1) 84(2)  -7(1) -2(1)  -4(1) 
C(20A) 45(1)  40(1) 111(2)  -32(1) -6(1)  -4(1) 
C(21A) 43(1)  58(2) 80(2)  -40(1) 1(1)  -5(1) 
C(22A) 30(1)  57(1) 48(1)  -24(1) -1(1)  -1(1) 
C(23A) 32(1)  27(1) 36(1)  -2(1) -9(1)  -1(1) 
C(24A) 34(1)  39(1) 34(1)  -1(1) -3(1)  8(1) 
C(25A) 34(1)  54(1) 38(1)  -13(1) -10(1)  10(1) 
O(4A) 45(1)  129(2) 40(1)  -2(1) 2(1)  44(1) 
C(26A) 31(2)  84(3) 52(2)  0(2) 0(2)  23(2) 
C(27A) 49(3)  136(5) 65(3)  3(3) 10(2)  35(3) 
O(4C) 45(1)  129(2) 40(1)  -2(1) 2(1)  44(1) 
Cl(1B) 38(1)  71(1) 34(1)  -2(1) 6(1)  -2(1) 
Cl(2B) 80(1)  79(1) 37(1)  -8(1) -8(1)  -31(1) 
O(1B) 58(1)  38(1) 44(1)  -3(1) 7(1)  3(1) 
O(2B) 48(1)  35(1) 34(1)  -7(1) 10(1)  -3(1) 
O(3B) 54(1)  48(1) 36(1)  11(1) 9(1)  8(1) 
O(4B) 67(1)  36(1) 46(1)  -3(1) 21(1)  1(1) 
N(1B) 28(1)  33(1) 32(1)  2(1) 0(1)  0(1) 
N(2B) 29(1)  35(1) 30(1)  -3(1) 2(1)  3(1) 
C(1B) 33(1)  33(1) 28(1)  0(1) 0(1)  0(1) 
C(2B) 30(1)  40(1) 28(1)  -2(1) 2(1)  3(1) 
C(3B) 25(1)  38(1) 36(1)  4(1) 3(1)  -5(1) 
C(4B) 24(1)  36(1) 48(1)  7(1) 1(1)  -7(1) 
C(5B) 31(1)  34(1) 55(1)  6(1) 4(1)  -4(1) 
C(6B) 47(1)  36(1) 80(2)  -2(1) 9(1)  -4(1) 
C(7B) 53(1)  33(1) 110(2)  21(1) 4(1)  -1(1) 
C(8B) 52(1)  50(1) 81(2)  29(1) 0(1)  -6(1) 
C(9B) 40(1)  50(1) 55(1)  20(1) 0(1)  -7(1) 
C(10B) 31(1)  46(1) 31(1)  -8(1) 0(1)  3(1) 
C(11B) 28(1)  48(1) 37(1)  -7(1) -1(1)  3(1) 
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C(12B) 26(1)  33(1) 34(1)  -1(1) -1(1)  8(1) 
C(13B) 33(1)  55(1) 42(1)  1(1) 5(1)  7(1) 
C(14B) 33(1)  105(2) 68(2)  -8(2) 10(1)  -22(1) 
C(15B) 54(2)  152(3) 80(2)  -47(2) 10(2)  -53(2) 
C(16B) 43(1)  108(2) 57(1)  -38(1) 3(1)  -26(1) 
C(17B) 33(1)  26(1) 39(1)  6(1) -5(1)  3(1) 
C(18B) 32(1)  39(1) 42(1)  6(1) 0(1)  6(1) 
C(19B) 33(1)  44(1) 54(1)  12(1) 5(1)  2(1) 
C(20B) 40(1)  44(1) 71(1)  13(1) -1(1)  -7(1) 
C(21B) 51(1)  37(1) 66(1)  2(1) -20(1)  -12(1) 
C(22B) 46(1)  30(1) 43(1)  4(1) -9(1)  -3(1) 
C(23B) 30(1)  43(1) 27(1)  5(1) 0(1)  1(1) 
C(24B) 47(1)  39(1) 35(1)  0(1) 9(1)  -1(1) 
C(25B) 34(1)  42(1) 30(1)  0(1) -2(1)  1(1) 
C(26B) 52(1)  37(1) 48(1)  -5(1) -5(1)  1(1) 
C(27B) 83(4)  44(2) 54(2)  -10(2) 11(2)  3(2) 
C(26D) 52(1)  37(1) 48(1)  -5(1) -5(1)  1(1) 
 
Table S-II-5.   Hydrogen coordinates ( x 104) and isotropic  displacement 
parameters (Å 2x 10 3) for d1309. 
 
 
x  y  z  U(eq) 
H(1AA) 11539 12347 5846 36 
H(2AA) 11429 12291 5186 35 
H(3AA) 12599 10739 5897 38 
H(6AA) 17356 10299 5508 53 
H(7AA) 17466 8612 5815 55 
H(8AA) 15700 7952 6084 51 
H(9AA) 13818 9041 6061 46 
H(10A) 11440 10500 5057 39 
H(13A) 9139 6972 5649 69 
H(14A) 9479 5828 5220 85 
H(15A) 10630 6579 4807 80 
H(16A) 11336 8547 4819 62 
H(19A) 13423 16188 5291 62 
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H(20A) 12793 17216 5731 79 
H(21A) 11721 16229 6116 73 
H(23A) 9795 13607 5259 38 
H(24A) 8862 12193 5727 43 
H(26A) 6397 15285 5800 67 
H(26B) 5439 14392 5628 67 
H(27A) 4634 14916 6110 125 
H(27B) 5880 14376 6267 125 
H(27C) 4908 13515 6093 125 
H(26C) 5300 14103 5632 50 
H(26D) 5131 13321 5939 50 
H(27D) 4977 15390 6050 83 
H(27E) 6381 15572 5918 83 
H(27F) 6162 14804 6222 83 
H(1BA) 1632 7277 3313 37 
H(2BA) 630 7243 2703 39 
H(3BA) 1969 5515 3469 40 
H(6BA) 3161 1912 2730 65 
H(7BA) 3425 779 3171 79 
H(8BA) 3026 1578 3648 73 
H(9BA) 2404 3562 3691 58 
H(10B) -1121 6238 2749 43 
H(13B) -3967 6382 3755 52 
H(14B) -5268 4989 3523 82 
H(15B) -4839 4330 3030 115 
H(16B) -3065 5014 2772 83 
H(19B) 5148 8279 2474 53 
H(20B) 6283 9131 2870 62 
H(21B) 5456 9123 3363 62 
H(23B) 1198 9301 2753 40 
H(24B) -797 9319 3164 48 
H(26E) -1495 13083 3049 55 
H(26F) 0 13085 3115 55 
H(27G) -1058 14167 3487 91 
H(27H) -400 13024 3638 91 
H(27I) -1894 13022 3572 91 
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H(26G) -1051 13096 2985 55 
H(26H) 13 13115 3249 55 
H(27J) -1871 14036 3429 81 
H(27K) -1588 12856 3623 81 
H(27L) -2646 12838 3361 81 
H(1OA) 14660(30) 11960(30) 5445(6) 75(8) 
H(2OA) 10050(30) 9900(30) 5702(6) 72(9) 
H(1OB) 2260(30) 4800(20) 2737(6) 59(7) 






































































Table S-II-7.  Hydrogen bonds for d1309  [Å  and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
 O(1A)-H(1OA)...N(1A) 0.92(3) 1.78(3) 2.630(2) 153(3) 
 O(2A)-H(2OA)...N(2A) 0.92(3) 1.77(3) 2.612(2) 150(3) 
 O(1B)-H(1OB)...N(1B) 0.88(3) 1.81(3) 2.601(2) 147(2) 
 O(2B)-H(2OB)...N(2B) 0.87(3) 1.78(2) 2.5682(19) 150(2) 





In Chapter III, 
 
Crystal structure of diimine 3 
 
Table S-III-1.  Crystal data and structure refinement for d12336. 
 
Identification code  d12336  
Empirical formula  C22 H24 N2 O6 
Formula weight  412.43  
Temperature  147(2) K  
Wavelength  1.54178 Å   
Crystal system  Monoclinic  
Space group  P 21  
Unit cell dimensions a = 6.9679(3) Å  = 90°. 
 b = 19.0540(9) Å  = 93.428(2)°. 
 c = 7.6683(4) Å   = 90°. 
Volume 1016.27(8) Å 3 
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Z 2  
Density (calculated) 1.348 Mg/m3  
Absorption coefficient 0.819 mm-1  
F(000) 436  
Crystal size 0.28 x 0.15 x 0.12 mm3 
Theta range for data collection 4.64 to 66.31°. 
Index ranges -8<=h<=7, -22<=k<=21, -9<=l<=9 
Reflections collected 12698  
Independent reflections 3412 [R(int) = 0.0305] 
Completeness to theta = 66.31° 97.8 %   
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7528 and 0.6930 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3412 / 1 / 283 
Goodness-of-fit on F2 1.067  
Final R indices [I>2sigma(I)] R1 = 0.0305, wR2 = 0.0761 
R indices (all data) R1 = 0.0306, wR2 = 0.0763 
Absolute structure parameter 0.16(14)  
Largest diff. peak and hole 0.175 and -0.217 e.Å -3 
 
Table S-III-2.  Atomic coordinates  ( x 104) and equivalent  isotropic 
displacement parameters (Å 2x 103) for d12336.  U(eq) is defined as one 
third of  the trace of the orthogonalized Uij tensor. 
 
 
x y z U(eq) 
O(1) 4456(2) 3221(1) 5202(2) 38(1) 
O(2) 6771(2) 6630(1) 10659(2) 37(1) 
O(3) 3030(3) 5554(1) 7322(3) 78(1) 
O(4) 4970(2) 6389(1) 6500(2) 31(1) 
O(5) 5173(3) 4783(1) 10189(3) 90(1) 
O(6) 5861(2) 3857(1) 8609(1) 26(1) 
N(1) 5003(2) 4582(1) 5374(2) 27(1) 
N(2) 7816(2) 5568(1) 8809(2) 26(1) 
C(1) 5994(3) 5204(1) 6119(2) 29(1) 
C(2) 7246(2) 4944(1) 7780(2) 27(1) 
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C(3) 3520(2) 4655(1) 4325(2) 29(1) 
C(4) 2443(2) 4058(1) 3611(2) 26(1) 
C(5) 2954(2) 3367(1) 4058(2) 27(1) 
C(6) 1909(3) 2804(1) 3314(2) 34(1) 
C(7) 364(2) 2932(1) 2158(2) 36(1) 
C(8) -206(3) 3611(1) 1750(2) 43(1) 
C(9) 831(3) 4167(1) 2467(2) 37(1) 
C(10) 7250(3) 5531(1) 4761(2) 38(1) 
C(11) 9532(2) 5640(1) 9476(2) 26(1) 
C(12) 10041(2) 6224(1) 10648(2) 24(1) 
C(13) 8639(2) 6690(1) 11209(2) 27(1) 
C(14) 9173(3) 7231(1) 12369(2) 32(1) 
C(15) 11075(3) 7311(1) 12937(2) 33(1) 
C(16) 12483(2) 6854(1) 12409(2) 33(1) 
C(17) 11965(2) 6313(1) 11279(2) 30(1) 
C(18) 8899(2) 4481(1) 7228(2) 34(1) 
C(19) 4482(3) 5728(1) 6719(2) 32(1) 
C(20) 3600(3) 6904(1) 7062(2) 36(1) 
C(21) 5945(2) 4536(1) 8996(2) 32(1) 
C(22) 4659(2) 3434(1) 9666(2) 34(1) 
 
Table S-III-3. Bond lengths [Å ] and angles [°] for d12336. 
 
O(1)-C(5)  1.354(2) 
O(1)-H(1O)  0.86(4) 
O(2)-C(13)  1.349(2) 
O(2)-H(2O)  0.86(3) 
O(3)-C(19)  1.184(2) 
O(4)-C(19)  1.318(2) 
O(4)-C(20)  1.453(2) 
O(5)-C(21)  1.186(2) 
O(6)-C(21)  1.327(2) 
O(6)-C(22)  1.4450(19) 
N(1)-C(3)  1.278(2) 
N(1)-C(1)  1.470(2) 
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N(2)-C(11)  1.280(2) 
N(2)-C(2)  1.467(2) 
C(1)-C(10)  1.533(2) 
C(1)-C(19)  1.542(2) 
C(1)-C(2)  1.579(2) 
C(2)-C(18)  1.532(2) 
C(2)-C(21)  1.549(2) 
C(3)-C(4)  1.453(2) 
C(3)-H(3A)  0.95 
C(4)-C(9)  1.399(2) 
C(4)-C(5)  1.401(2) 
C(5)-C(6)  1.398(2) 
C(6)-C(7)  1.375(3) 
C(6)-H(6A)  0.95 
C(7)-C(8)  1.384(3) 
C(7)-H(7A)  0.95 
C(8)-C(9)  1.379(3) 
C(8)-H(8A)  0.95 
C(9)-H(9A)  0.95 
C(10)-H(10A)  0.98 
C(10)-H(10B)  0.98 
C(10)-H(10C)  0.98 
C(11)-C(12)  1.461(2) 
C(11)-H(11A)  0.95 
C(12)-C(13)  1.407(2) 
C(12)-C(17)  1.408(2) 
C(13)-C(14)  1.398(2) 
C(14)-C(15)  1.379(2) 
C(14)-H(14A)  0.95 
C(15)-C(16)  1.389(3) 
C(15)-H(15A)  0.95 
C(16)-C(17)  1.382(2) 
C(16)-H(16A)  0.95 
C(17)-H(17A)  0.95 
C(18)-H(18A)  0.98 
C(18)-H(18B)  0.98 
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C(18)-H(18C)  0.98 
C(20)-H(20A)  0.98 
C(20)-H(20B)  0.98 
C(20)-H(20C)  0.98 
C(22)-H(22A)  0.98 
C(22)-H(22B)  0.98 































































































Symmetry transformations used to generate equivalent atoms:  
 
Table S-III-4. Anisotropic displacement parameters (Å 2x 103) for d12336. 
The anisotropic displacement factor exponent takes the form: -2p2[ h2 
a*2U11 + ...  + 2 h k a* b* U12 ] 
 
 
U11 U22  U33 U23 U13 U12 
O(1) 46(1)  23(1) 43(1)  0(1) -17(1)  -1(1) 
O(2) 29(1)  38(1) 43(1)  -15(1) -3(1)  5(1) 
O(3) 74(1)  42(1) 128(2)  -39(1) 76(1)  -28(1) 
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O(4) 30(1)  22(1) 40(1)  5(1) 6(1)  3(1) 
O(5) 147(2)  37(1) 97(1)  -25(1) 98(1)  -31(1) 
O(6) 29(1)  22(1) 28(1)  1(1) 4(1)  -4(1) 
N(1) 38(1)  21(1) 22(1)  -2(1) 6(1)  -4(1) 
N(2) 30(1)  22(1) 27(1)  -3(1) 5(1)  -4(1) 
C(1) 38(1)  22(1) 27(1)  -3(1) 10(1)  -8(1) 
C(2) 31(1)  22(1) 30(1)  -6(1) 10(1)  -6(1) 
C(3) 37(1)  22(1) 29(1)  2(1) 7(1)  2(1) 
C(4) 30(1)  25(1) 22(1)  -1(1) 4(1)  0(1) 
C(5) 31(1)  27(1) 24(1)  0(1) 1(1)  -1(1) 
C(6) 40(1)  28(1) 32(1)  -3(1) 3(1)  -8(1) 
C(7) 33(1)  46(1) 30(1)  -5(1) 4(1)  -14(1) 
C(8) 30(1)  59(1) 39(1)  4(1) -5(1)  -5(1) 
C(9) 34(1)  39(1) 37(1)  5(1) -1(1)  5(1) 
C(10) 49(1)  30(1) 37(1)  -2(1) 20(1)  -8(1) 
C(11) 28(1)  24(1) 27(1)  0(1) 8(1)  -1(1) 
C(12) 28(1)  21(1) 25(1)  2(1) 5(1)  -3(1) 
C(13) 28(1)  27(1) 27(1)  2(1) 0(1)  3(1) 
C(14) 37(1)  29(1) 30(1)  -4(1) -3(1)  6(1) 
C(15) 42(1)  28(1) 28(1)  -2(1) -4(1)  -3(1) 
C(16) 30(1)  39(1) 29(1)  1(1) -2(1)  -6(1) 
C(17) 26(1)  34(1) 30(1)  2(1) 6(1)  -1(1) 
C(18) 33(1)  28(1) 41(1)  -11(1) 15(1)  -7(1) 
C(19) 39(1)  27(1) 30(1)  -8(1) 10(1)  -10(1) 
C(20) 39(1)  32(1) 38(1)  2(1) 4(1)  11(1) 
C(21) 38(1)  25(1) 32(1)  -5(1) 12(1)  -5(1) 
C(22) 35(1)  29(1) 37(1)  5(1) 8(1)  -8(1) 
 
Table S-III-5. Hydrogen coordinates ( x 104) and isotropic  displacement 
parameters (Å 2x 10 3) for d12336. 
 
 
x  y  z  U(eq) 
H(3A) 3110 5115 4003 35 
H(6A) 2265 2335 3607 40 
H(7A) -322 2548 1631 44 
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H(8A) -1303 3693 981 51 
H(9A) 443 4633 2180 44 
H(10A) 6428 5754 3838 57 
H(10B) 8029 5165 4251 57 
H(10C) 8098 5885 5327 57 
H(11A) 10489 5308 9206 31 
H(14A) 8228 7543 12765 39 
H(15A) 11431 7686 13706 40 
H(16A) 13786 6914 12820 40 
H(17A) 12919 5996 10923 36 
H(18A) 9485 4239 8254 50 
H(18B) 9868 4773 6703 50 
H(18C) 8403 4133 6372 50 
H(20A) 3930 7368 6614 54 
H(20B) 3643 6917 8341 54 
H(20C) 2303 6774 6609 54 
H(22A) 4701 2945 9281 50 
H(22B) 3333 3606 9541 50 
H(22C) 5130 3466 10894 50 
H(1O) 5060(50) 3600(20) 5470(40) 100(12) 
H(2O) 6700(30) 6265(13) 10000(30) 50(6) 
 

































































Symmetry transformations used to generate equivalent atoms:  
 
Table S-III-7. Hydrogen bonds for d12336 [Å  and °].  
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
 O(1)-H(1O)...N(1) 0.86(4) 1.87(4) 2.6232(17) 146(3) 
 O(1)-H(1O)...O(6) 0.86(4) 2.48(3) 2.9914(17) 119(3) 
 O(2)-H(2O)...N(2) 0.86(3) 1.82(3) 2.6006(18) 151(2) 







다이아자 코우프 자리바꿈 반응기법에 근거한 키랄 
다이아민 기반 구조체들의 설계, 합성 및 응용 
 
다이아자 코우프 자리바꿈 반응 기법(DCR) 에 근거한 합성법은 
공명지원 수소결합 (RAHB) 을 그 추진력으로 하는 방법이며, 이는 
다양한 C2-대칭적 구조를 가지는 키랄 다이아민 뿐 아니라 비대칭의 
키랄 다이아민을 합성하기 위한 유용한 방법으로 사용되어 왔다. 
토론토 대학의 Jik Chin 교수에 의해서 이와 같은 자리바꿈 반응에 
대한 연구가 소개된 후, 자리바꿈 반응 기법을 이용하여 합성된 
다이아민을 기반으로 한 다양한 전이금속 촉매나 유기촉매의 개발 
및 그 응용에 대한 연구가 더욱 활발히 진행되어 왔다. 그리고 
자리바꿈 반응기법의 쉽고 효율적인 합성법을 바탕으로 다이아민을 
포함하는 구조체에 입체적·구조적 변화나 다이아민의 전기적 
다양성을 도입하여 촉매의 반응성 및 선택성을 향상시키고자 하는 
연구가 많이 진행되어 왔다. 하지만, 현재까지 다이아자 코우프 
자리바꿈 반응을 이용한 촉매 개발과 그 활성 향상에 대한 
연구와는 달리, 생리적 활성을 띄는 물질의 주요 구조가 될 수 있는 
다이아민을 포함한 골격 합성에 대한 연구의 예는 많이 알려지지 
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않은 실정이다.  
본 연구는 다이아자 코우프 자리바꿈 반응기법에 의한 키랄 
다이아민의 효율적 합성법에 근거하여, 다양한 키랄 구조체를 
준비하기 위한 좋은 중간체로써 사용할 수 있는 비대칭적으로 
치환기가 도입된 다이아민을 합성하고자 하였으며 이는 모계 키랄 
다이아민과 각기 다른 알데하이드를 시작물질로 하여 이로부터 
비대칭적으로 치환된 다이아민 구조체의 합성이 가능할 것이라고 
예측하였다. 이와 같은 방법으로 생리적 활성을 띄는 물질들의 기본 
골격구조에서 많이 확인할 수 있는 trans-3-아릴피페라진-2-
카복실산 유도체와 γ,δ-다이아미노산 유도체들을 합성하였다. 
그리고 기존에 금속이나 라디칼 개시인자를 이용한 반응으로 주로 
합성된 아미노산의 이합체 구조를 모계 키랄 다이아민을 이용한 
입체특이적 합성법을 통하여 합성하였으며, 이를 DFT 계산과 
결정구조 분석법을 통하여 그 원리 및 입체적 특이성을 확인하였다. 
추가적으로 다양하게 사용되고 있는 C2-대칭적 구조를 지닌 
다이아민의 광학적 순도를 확인하기 위해 라이보스와 아라비노스와 
같은 단당류물질을 비대칭의 유도체 (Chiral derivatizing agent) 로써 
사용하는 연구를 진행하였다.  
